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1.1 Defining epigenetics 
The study of epigenetics in some form has existed since the 17th century in the form of the study of 
epigenesis which defined as “the process by which plants, animals and fungi develop from a seed, 
spore or egg through a sequence of steps in which cells differentiate and organs form” (1). 
Epigenesis was the school of thought that opposed preformatism, which was largely refuted in 
favour of epigenesis in 1762. In 1942, from epigenesis, the word “epigenetic” was coined, and 
used as an adjective to describe the differentiation of totipotent stem cells in embryonic 
development. However the precise definition of what epigenetics studied, epigenetic traits, wasn’t 
agreed upon until 2008. “Epigenetic trait” was defined there as a “stably heritable phenotype 
resulting from changes in a chromosome without alterations in the DNA sequence" (2). 
 
According to this definition, epigenetics covers a large amount of modifications. These 
modifications includes alterations via: covalent modifications, RNA transcripts, mRNA, microRNA 
and sRNA.  Covalent modification of histones and DNA play a central role in epigenetic 
inheritance and as a result, the word "epigenetics" is sometimes used as a synonym for these 
processes. It should be noted that this is misleading as chromatin remodelling is not always 
inherited, and not all epigenetic inheritance involves chromatin remodelling (3). Due to the 
importance of covalent modifications in epigenetics and relevance to this thesis they will be the 





1.2 Epigenetic modifications 
 
1.2.1 Histone modifications 
Histone proteins are responsible for organising and packaging DNA. They do this by forming 
histone-DNA structural octamers called ‘nucleosomes’. These nucleosomes form a larger complex 
called ‘chromatin’.  The histone complex is made up of core histones called H2A, H2B, H3, H4, 
and a linker histone called H1.  
 
The principle mechanism through which histones can bind to the DNA is because histones have a 
net positive charge and DNA has a net negative charge – they thus attract one another with ionic 
forces. As a result histone modifications typically exert their effects through modification of the 
histone’s charge to better attract or repel the DNA strand. The aforementioned modifications occur 
primarily on their N-terminal tails, and in their globular domains (4, 5). These modifications 
include methylation, acetylation, citrullination, phosphorylation, ubiquitination, SUMOylation, and 
ADP-ribosylation.   
1.2.2 DNA Methylation 
DNA methylation is the process where the cytosine in a cytosine-phosphate-guanine motif (CpG) 
gets turned into 5-methylcytosine (5mC). The process is carried out by DNA methyltransferases 
(DNMTs). Three DNMTs (DNMT1, DNMT3a and DNMT3b) are required for establishment and 
maintenance of DNA methylation patterns. DNMT1 is responsible for the maintenance of 
established patterns of DNA methylation, while DNMT3a and 3b mediate establishment of new 
DNA methylation patterns. The overall effect of DNA methylation is gene suppression, however 
there are a few examples of DNA methylation upregulating expression. DNA methylation achieves 
transcriptional suppression by directly preventing transcription factor binding and leads to changes 
in chromatin structure that restrict access of transcription factors to the gene promoter (6, 7) – 
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therefore downregulating transcription and gene expression. 
 
Due to their susceptibility to methylation, CpGs are highly mutagenic and through evolutionary 
processes genomes are consequently CpG deficient (7, 8). However CpGs do occur in high 
density in regions across the genome, these high density CpG regions are called CpG islands 
(CGIs). CGIs have been defined as being regions less than 500bp with a GC percentage greater 
than 60% and an observed:expected ratio of CpGs greater than 0.6. 
 
In humans approximately 70% of known gene promoters are associated with a CGI, making this 
the most common promoter type in the vertebrate genome (8, 9). Nearly all of the housekeeping 
genes, as well as a proportion of tissue-specific genes and developmental regulator genes (10,11). 
More recent studies uncovered a large class of CGIs that are remote from annotated transcription 
start sites (TSSs), but still show evidence for promoter function (12,13). These findings emphasise 
the strong correlation between CGIs and transcription initiation.  
 
Methylated CpGs can also become demethylated. The process of DNA demethylation can occur 
either actively or passively via a cyclic enzymatic cascade. 
Passive DNA demethylation occurs during DNA replication, the DNA methylome maintenance 
machinery, DNMT1/ UHRF1, is responsible for copying the CpG methylation pattern by 
methylating the unmodified cytosine in the nascent DNA strand (14,15). Ergo, passive loss of 5mC 
can therefore be achieved through multiple cycles of DNA replication in the presence of 
dysfunctional methylome maintenance machinery. This demethylation process is termed 
‘replication-dependent passive DNA demethylation’, an example of such is the erasure of 5mC 
from the maternal genome during mouse preimplantation development (16,17). 
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Active DNA demethylation is the process where 5mC can also be rapidly demethylated 
independently of DNA replication. Such change involves active DNA demethylation mechanisms, 
which require one or more enzymatic reactions to modify or remove 5mC - these reactions are 
catalysed by TET enzymes (18).  The step-wise cytosine modification pathway that includes 
cytosine methylation by DNMTs and step-by-step oxidation of 5mC by TET proteins. DNMTs use 
S-adenosylmethionine (SAM) as a methyl donor to catalyse methylation at the 5-position of 
cytosine, yielding S-adenosylhomocysteine (SAH). As Fe2+/a-ketoglutarate (a-KG)-dependent 
dioxygenases, TET proteins then use a base-flipping mechanism to flip the target base out of the 
DNA into the catalytic site (19-21). The active site, Fe2+ is bound by conserved amino acid 
residues in TETs. TET enzymes use molecular oxygen as a substrate to catalyse oxidative 
decarboxylation of a-KG, yielding CO2, enzyme-bound succinate, and a reactive highvalent Fe4+-
oxo intermediate. The TET-bound Fe4+-oxo intermediate reacts with 5mC/ 5hmC/5fC to generate 
5hmC/5fC/5caC. In mammals, base excision repair of 5fC/5caC completes the DNA demethylation 
process (18). 
1.3 Environmental factors and epigenetic changes 
This section will address how epigenetic changes can be brought about by diet, chemical 
pollutants, temperature changes and other external stresses.  
For instance, animal models have shown that nutrition and exposure to environmental factors 
during development can cause region-specific changes in the epigenome (22).  
For example, in humans, there is growing awareness that nutrition and exposure to toxic 
components may have long-term phenotypic effects (23). As is discussed below, human studies 
on the gestational effects of nutrition have thus far identified DNA methylation changes that are 
relatively small (24-26). However the relevance of these minor changes, and whether they are a 
consequence or cause of the observed developmental and metabolic aberrations is still something 
that needs to be addressed by future studies. 
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1.3.1 Gestational effects.  
The degree of impact that environmental factors have on the mammalian epigenome seems to 
depend on what developmental stage the organism is at. Several lines of evidence suggest that 
the gestational period is particularly susceptible to epigenetic insult, and that the environment can 
have different effects on the embryo and placenta.  
 
The early conceptional and embryonic stages of development seem particularly sensitive to 
nutritional influence upon epigenetic modifications. Studies on the ‘Dutch hunger winter’, at the 
end of the Second World War, indicate that famine exposure in the early conceptional period led to 
adverse metabolic and mental phenotypes in the following generation. Initial studies reported a 
minor, but significant, decrease in DNA methylation at a differentially methylated region (DMR) in 
the imprinted insulin-like growth factor 2 (IGF2) gene (27). Further research (24-26) identified 
small alterations in DNA methylation at other imprinted genes such as insulin (INS), maternally 
expressed gene 3 (MEG3) and guanine nucleotide binding protein a-stimulating (GNAS). 
Importantly, epigenetic alterations were also found at some loci that are involved in growth and 
implicated in metabolic disease, such as ATP-binding cassette A1 (ABCA1), leptin (LEP) and 
interleukin 10 (IL10). It should also be noted that famine exposure later during gestation had no 
significant effects on DNA methylation (24).  
 
Another example of nutrition-induced epigenetic changes can be seen in the increased incidence 
of type 2 diabetes in rats when exposed to sub-optimal nutrition during early development. This 
was associated with the epigenetic repression, in pancreatic islets, of hepatocyte nuclear factor 4a 




1.3.2 Postnatal effects 
Environmental conditions can affect the epigenome postnatally as well, for instance one 
epidemiological study identified a possible link between particulate air pollution and genome-wide 
DNA methylation in blood cells (29). Genome-wide methylation was also altered in the blood of 
individuals that had been exposed to the carcinogen, benzene.  
 
Epidemiological studies on skin and other tissues identified locus-specific DNA methylation 
changes associated with various environmental factors, including chronic exposure to sunlight, 
asbestos and tobacco smoke, consumption of alcohol and use of hair-dye (30-32). 
  
However a possible confounding factor in these studies is that environmental stress can alter the 
relative abundance of different cell types in the blood. Such shifts could lead to altered levels of 
measured DNA methylation for specific genes. In addition, DNA methylation itself is associated 
with cell fate determination in haematopoiesis, and as a result alterations to this methylation 
pattern could affect the cell populations that constitute peripheral blood (33). To avoid such 
confounding effects, ideally individual cell types and tissues should be explored as well, if 
experimental design allows it. 
 
In these and similar studies, it is also unknown whether the observed epigenetic changes are 
directly mediated by the toxic compound under study. Because not all tissues of an adult organism 
are equally exposed to chemical pollutants, and because sensitivity depends on the tissue type, 
epigenetic alterations in adults are probably tissue-specific in nature. However most human 




The reason for the difference in sensitivity to epigenetic alterations between postnatal could be 
linked to the level of cell pluripotency. Several studies have shown that the epigenomes of fully 
differentiated cells seem to be relatively stable in comparison to the epigenome of mouse 
embryonic stem cells which are particularly sensitive to in vitro culture conditions (34-37). Also, 
culture of mammalian pre-implantation embryos can readily affect the establishment and 
maintenance of DNA methylation, particularly at imprinted genes (34-37).  
 
This increased sensitivity towards extrinsic factors inducing epigenetic changes is thought to be to 
do with the fact that early embryonic cells have higher expressions of genes involved with the 
regulation of the epigenome – DNA methyltransferases (DNMT). As a result, the increased amount 
of these regulatory machineries in early embryos, stem cells and germ cells is a likely cause of the 
susceptibility of these pluripotent cell types to environmental signals (34-37).  Taken together it 
can be seen that the degree to which a cell is epigenetically modified by external cues depends 
upon how epigenetically malleable the cells at that time are.   
 
 
1.3.3 Transgenerational inheritance 
 There has been research conducted in order to answer to question of whether environmentally-
induced epigenetic alterations can be passed down from one progeny to the next (38). During 
gametogenesis, the epigenome is reprogrammed genome-wide in mammals. This remodelling 
processes make the gonadal cells particularly sensitive to environmental factors; this is so even in 
adults, and could explain why potential transgenerational effects are observed (39-42). 
 
A truly epigenetic transgenerational inheritance would mean that the parent organism already had 
the epigenetic change and transmitted the change to its progeny, without the progeny being 
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exposed to the causative factor. Therefore true transgeneration epigenetic marks are classed as 
such if they transmit to the F3 generation. This is because the developing germ cells that give rise 
to the F2 generation are already present, and could thus have been exposed to the same extrinsic 
factors, during the embryonic development of the F1 generation (43-44). 
 
However, only in exceptional cases are DNA methylation-associated phenotypes inherited from 
one generation to the next. The genome-wide DNA demethylation and chromatin remodelling that 
occurs in the germ cells of the developing embryo typically prevent this from happening (39,45). 
However, there are sequences in the genome that are relatively resistant to the genome-wide DNA 
methylation reprogramming and it only takes one of the mating pair to possess these inheritable 
epigenetic marks (46). For example, a 2011 study found that the effects of stress can be 





1.3.4 Diet, lifespan and ageing 
Dietary components have been linked to changes in DNA methylation such as: folate, vitamin B6, 
vitamin B12, betaine, methionine and choline. These nutrients can all affect the pathways of ‘one-
carbon metabolism' that dictate the levels of the methyl-donor available for DNA methylation and 
histone methylation - S-adenosylmethionine (SAM). Although the availability of methyl donors 
might be expected to induce a genome-wide effect on the epigenome, only region-specific effects 
have been reported in several studies (48,49). 
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Additionally, nutrient availability is also key in epigenetically altered lifespan (50).  
Two key factors that appear to affect lifespan via epigenetic modification are the insulin signalling 
pathway and calorie restriction. The insulin and insulin-like growth factor 1 (IGF1) signalling 
pathway is well understood in regards to ageing. Nutrient sensing by insulin/IGF1 engages a 
cascade which results in inactivating and promoting the cytoplasmic sequestration of the 
transcription factor DAF16. Under calorie restriction, DAF16 is instead sequestered in the nucleus 
in which it can activate genes that promote longevity (51,52). 
Various lines of evidence support this pathway, as it was shown that mutations in the age-1 gene 
lengthen lifespan (53). Subsequently, another study showed that mutations in DAF2 increase 
worm lifespan two-fold (54). It was further shown that DAF16 mutations suppressed longevity 
phenotypes of AGE1 and DAF2, suggesting that they functioned in the same pathway (55,56). 
Additionally, it was found that a high glucose diet decreased rate of dauer formation, the stasis-like 
state used to survive harsh conditions, shortened lifespan of DAF2 knockdowns, decreased DAF-
16 activity, and shortened lifespan of wild type worms. In contrast, disabling DAF2 halted larval 
development in the dauer formation that shows increased lifespan, inhibited reproductive maturity, 
and delayed onset of senescence (54,57).  
Not only have epigenetics been shown to effect lifespan but ageing itself has been shown to effect 
epigenetics. For instance, ageing has found to be linked to genome-wide loss of histones. The 
evidence for this is linked to cell division, specifically, replicatively-aged yeast were shown to have 
a genome-wide nucleosome loss of approximately 50%, in comparison to wild-type, which in turn 
leads to transcriptional deregulation (58). In addition, long-living strains of yeast are found to 
overexpress histones (59). In addition, ageing has been associated with dysfunctional histone 
activation and repression; as highlighted by a 2010 study which shows that levels of H3 histone 
methylation on lysine residue 27 (H3K27me3) are related to lifespan (60), these effects are also 
transgenerational (61). 
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Another genetic consequence of ageing is an altered transcriptional 'program', something that has 
been repeatedly highlighted in senescent human cells. These cell lines remodel the epigenetic 
mosaic to induce cellular defence and inflammatory genes, many of which the senescent cell 
secretes (62). These alterations to the cell are part of the senescence-associated secretory 
phenotype (SASP). SASP is thought to up-regulate immune clearance of pre-malignant senescent 
cells and in turn aid in tumour suppression. Chronic SASP on the other hand, is thought to 
promote tissue ageing (63). 
In support of these data, a strong correlation was demonstrated between the loss of H3K27me3 
and the up-regulation of SASP genes in senescent cell lines (64). Additionally, inhibition of the 
H3K4 methyltransferase, MLL1, was shown to indirectly reduce the SASP (65). Ergo, these 
studies indicate that transcriptional reprogramming in senescent cells occurs through the altered 
activity of certain epigenetic machinery.  
The SASP can be seen in haematopoietic stem cells (HSCs) from aged mice as they show an up-
regulated inflammatory response and down-regulated chromatin remodelling, transcriptional 
repression, and DNA repair in comparison to younger murine controls (66). An in-depth analysis 
revealed that genes related to cell proliferation, cell adhesion, and ribosomal protein (RP) genes 
were up-regulated while those related to cell cycle, DNA replication and DNA repair were down-
regulated (67).  
In addition to histone modifications, age-induced genome-wide alterations to DNA methylation is 
demonstrable in mammalian models (68). Data supports the model that ageing progressively 
increases genome-wide heterochromatin deregulation. The DNA hypomethylation occurs primarily 
in repetitive regions of the genome that correlate with the presence of conserved heterochromatin, 
while hypermethylation primarily occurs at promoter CpGs. 
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In murine models, age-induced hypomethylation in liver is apparent as the models age from 6-24 
months (69). A study of livers from long-lived murine strains showed lower basal levels of DNMT1 
regulated by growth hormone deficiency in comparison to normal murine models. The differential 
expression of DNMT is thought to cause these DNA methylation differences and impact lifespan by 
modifying lifespan-related genes (70). 
It has been demonstrated that DNA methylation can serve as an effective predictor of age in non-
cancerous tissues. A study identified that DNA methylation at 353 CpGs, termed ‘clock’ CpGs, and 
no other epigenetic modifications was an accurate predictor of age (71, 72). A study conducted in 
parallel to these, investigated the rate of DNA methylation change by building a predictive model of 
how ageing affected the methylome in individuals aged 19–101 years old. A smaller set of 71 
CpGs were identified that have a very high accuracy of age-prediction and occur near age-related 
genes. The smaller number of CpGs identified increased the diagnostic value of ‘clock’ CpGs (73). 
Taken together it can be seen that ageing is correlated with progressive loss of epigenetic control 
through histone loss, and DNA hypomethylation. Also it shows that lifespan is related to the levels 
of epigenetic dysfunction. Furthermore that epigenetic differences in senescent cells can affect 









1.4 Epigenetics in disease 
1.4.1 Epigenetics in Cancer 
The epigenome of normal cell undergoes vast changes after they turn into cancerous cells (74, 
75). These epigenetic changes, dubbed “epimutations”, along with widespread genetic mutations, 
play a decisive part in the initiation and progression of cancer (76).  
The epimutations result in a genome-wide dysregulation of gene expression leading to the 
development and progression of cancer. This is possible as epimutations can result in silencing of 
tumour suppressor genes and activating oncogenes independently to and in concert with 
deleterious genetic mutations. Epimutations therefore serve as a second 'hit' that further drives the 
cell towards a cancerous phenotype (77). As epimutations can be passed on through cell division, 
they are selected for in a rapidly growing cancer cell population and therefore would confer a 
growth advantage to tumour cells further exacerbating their uncontrolled growth. 
DNA methylation undergoes profound changes during cancer initiation and progression. These 
changes were the first epimutations identified in cancer (78). A cancerous epigenome is consists 
of both genome-wide hypomethylation and site-specific CGI hypermethylation (76). It is thought 
that they contribute to cancer initiation due to some changes occurring very early on in cancer 
development (79). 
The genome-wide DNA hypomethylation plays a significant role in tumour formation and occurs at 
various genomic regions including CpG-poor promoters, repetitive elements, introns and gene 
deserts (80). Hypomethylation in these regions all contribute towards genomic instability (76,81). 
DNA hypomethylation and genomic instability is implicated in a wide variety of human cancers (81, 
82). In contrast, CGI hypermethylation silences tumour suppressor genes and in doing so 
contributes to tumorigenesis. Various tumour suppressor genes have been shown to be silenced 
by hypermethylation in cancer p16, MLH1 and BRCA1 (74, 76, 83). These genes are involved in 
DNA repair, cell cycle, cell adhesion, apoptosis and angiogenesis – all of which are fundamental to 
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cancer initiation and progression. 
It is interesting to note that regions that are hypermethylated in cancer are often pre-marked with 
H3K27me3 mark in embryonic stem cells (84) suggesting a link between the regulation of 
development and tumourigenesis. This observation partially explains the theory that there is 
organised methylation of a subset of CpG islands in tumours (84).  
Whilst it is known that DNA methylation and histone modifications work independently and in 
concert to alter gene expression which provides a selective advantage for tumorigenesis; the 
mechanism by which these epigenetic abnormalities are acquired during cancer development is 
still not fully understood. It is postulated that it is unlikely that the epimutations found in cancer cell 
have occurred in a random fashion over several cellular divisions. It is more likely that the 
epimutation accumulations seen are the result of initial disturbances, in progenitor cells, to the 
epigenetic modification machinery. Such initial insults could predispose affected cell towards 
tumorigenesis – this model has been dubbed the “cancer stem cell model” (79). 
In summation, can be seen that attaining a better understanding of how specific genomic regions 
are targeted for DNA hypermethylation in cancer would likely lead to additional therapeutic targets. 
1.4.2 Epigenetics in autoimmune disorders 
During the adaptive immune response, T cells become mobilised when they encounter antigen 
presenting cells (APCs) such as B cells, dendritic cells (DCs), macrophages or Langerhans cells. 
APCs present the T cell with an antigen which if complementary with the T cell's MHC receptor 
mature the T cell. The MHC-antigen complex results in cytokine production by the T cell which 
stimulate T cell growth. Some T cells become T helper cell, also called CD4+ T cells, which attract 
and direct macrophages, neutrophils and lymphocytes to the area of inflammation. Other T cells 
become cytotoxic T cells, also known as CD8+ T cells. Another subset of T cells form in the 
maturation process, memory T cells, which stay in an inactive state, for potentially a long period of 
time, until they encounter the antigen again. Perturbations to the adaptive immune response can 
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see it being directed at the host's body.    
These perturbations to immune system that result an auto-reactive condition share a lot of 
similarities. Autoimmune conditions typically differ in regards to whether the immune response is 
localised or systematic, and what antigens the immune response targets. SLE, SSc, Sjorgens, and 
RA all result in joint damage and systematic inflammation. However RA is the only whose 
pathology primarily revolves around joint damage and degradation.  
These immune system perturbations have been associated with aberrations to epigenetic 
mechanisms. These epigenetic mechanisms can that influence these perturbations can be seen in 
the pathogenesis of four of the most prevalent autoimmune diseases: Systemic lupus 
erythematosus (SLE), Rheumatoid arthritis (RA), systemic sclerosis (SSc), and Sjogren’s 
syndrome (SS). Although RA will be the autoimmune system that will be focused on in this thesis, 
the contributions of aberrant DNA methylations to these disease pathologies will be examined (85) 
 
1.4.2.1 Systemic lupus erythematosus 
In regards to epigenetic modification, systemic lupus erythematosus (SLE) is one of the most well-
studied autoimmune diseases. SLE is a chronic autoimmune disease that is characterized by the 
production of autoantibodies that target a variety of nuclear antigens - consequently the disease 
can target many organ systems.  
Evidence suggests a strong interaction between the environment and the epigenome in the 
development of SLE. For example SLE CD4+ T cells that were treated with DNA methylation 
inhibitors were converted to autoreactivity. In addition, the introduction of synthetically 
demethylated CD4+ T cells into murine models resulted in the onset of a lupus-like syndrome 
(86,87). Pharmacological evidence is also supportive of this as two medications known to induce 
drug-induced lupus were found to inhibit methylation and produce murine lupus. It is thought that 
these drugs caused this by either by blocking the activity of the maintenance of DNA 
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methyltransferase DNMT1 or the ERK signalling pathway (88). 
Some biological features of SLE actually contribute towards DNA hypomethylation and disease 
pathogenesis. There is strong evidence that apoptotic DNA is important in inducing autoimmunity. 
For example DNA taken from stimulated lymphocytes that is placed into murine models is capable 
of causing an autoimmune disease which resembles human SLE. However the autoimmune 
development seemed to be dependent upon the DNA’s level of methylation as only the 
hypomethylated apoptotic DNA induced an autoimmune response (89). Though this effect didn’t 
seem dependent on the DNA being ‘apoptotic’, as demethylation of necrotic or normal DNA via 
drug treatment, when injected, caused an autoimmune response similar to that seen with apoptotic 
DNA (89). These reactions are thought to be mediated by signalling of an innate immune-response 
receptor - Toll-like receptor 9 (TLR9) (90). 
Peripheral blood mononuclear cells (PBMCs) of SLE patients have also been shown to possess 
changes in DNA methylation upon exposure to moderate to high levels of ultraviolet radiation, 
independent of the transcriptional activity of DNMT1. This would likely suggest an epigenetic 
component to the photosensitive rash seen in SLE patients (91). 
Dysregulation of ERK signalling is known to be involved in SLE pathogenesis. A study found that 
murine models with an inducible ERK signalling block, a pathway known to be upstream of the 
maintenance DNA methyltransferase DNMT1. Upon induction, this murine model demonstrated 
hypomethylation and upregulation of CD11a, as well as autoantibody production and the 
production of interferon-regulated genes (92). Furthermore, data on oxidative stress in SLE also 
reflect this as increased oxidative stress results in decreasing signalling through the ERK pathway, 
previously identified as key to DNMT1-mediated DNA methylation (93) 
Many a gene’s level of methylation has been tied to SLE pathogenesis and progression. For 
example in CD4+ T cells, TGAL (CD11a) is involved in both cellular adhesion and co-stimulation. 
CD11a has been found to be overexpressed in SLE, this is likely due to the upstream promoter of 
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CD11a being demethylated; the degree of this demethylation is also correlated with disease 
activity (94).  
 
IL10 is a cytokine pivotal to the development of both human and murine lupus. It is a well-
described lupus-susceptibility gene overexpressed in lupus CD4+ T cells and functions to regulate 
many important other via several signalling pathways. It is significantly hypomethylated in SLE 
patients compared to disease-free controls. (95) 
Genes encoded on the X chromosome are investigated as they possess relevance to SLE 
pathology. Specifically given that SLE is predominant in females and there is an apparent gene-
dose effect (96). An example of a relevant SLE-associated T cell gene located on the X 
chromosome is CD40L, which is a type II transmembrane protein. Furthermore, elevations of 
soluble CD40L are found in human SLE patients and several lupus mouse models (97, 98). 
This CD40L gene hypomethylation is at least partly drives its overexpression. This has been 
shown via treatment of human T cells with DNA methylation inhibitors or ERK pathway inhibitors 
which in turn hypomethylate the CD40L gene promoter sequences, lead to overexpression of 
CD40L, and were also found to be  sufficient to cause T cell auto-reactivity in vitro (99). It can be 
seen that female SLE patients have roughly double the expression of CD40L compared to their 
male counterparts, considering females have twice as many X chromosomes as men then it could 
be a possible explanation for this apparent gene-dose effect (100). 
A genome-wide methylation survey found that a SLE-afflicted twin in monozygotic twins 
possessed lower DNA methylation content than the healthy twin. This was found to be associated 
with significant reduction in expression levels of both DNMT1 and  DNMT3b. Additionally, 49 
genes were found to be differentially methylated in the SLE-afflicted twin, which had multiple 
functional ontologies, such as: defence response, cell activation, immune response, cell 
proliferation, and cytokine production (101). 
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A study analysed 27,000 CpG sites in CD4+ T cells of female SLE patients were compared to 
HCs. 337 CpG sites were found to be differential methylated, of this 337 approximately 70% were 
hypomethylated, and several methylation associations with SLE were found. For example, Matrix 
metalloproteinase 9 (MMP9), which has also found to be overexpressed in Sjogren’s syndrome 
and RA, was hypomethylated (102). PDGFRA was also found to be hypomethylated, and had 
been previously identified as a target of autoantibodies in active SLE patients (103). A gene 
pathway analysis was conducted and it identified pathways and ontologies which were significantly 
overrepresented amongst the differentially methylated genes, the most prominent of which 
included folate biosynthesis, which is involved in production of the methyl-donor needed for DNA 
methylation. Multiple transcription factors were also overrepresented, including RUNX3, which 
interacts with the promoter region of the previously mentioned, CD11a. The last observation drawn 
from this study was that there was a significant correlation between the DNA methylation pattern of 
several genes and clinical disease activity (104). The same research group hypothesised that 
alterations in DNA methylation were a cause of human SLE rather than a response to the 
presence of disease.  
 
They used a more comprehensive platform that would analyse over 485,000 CpGs and used it to 
examine the effects of differential methylation naïve CD4+ T cells from SLE patients. This 
identified 86 differentially methylated CpG sites and again approximately 70% of the CpGs were 
hypomethylated. These data were further verified as several genes were similarly differentially 
methylated as they were in the previous study with total CD4+ T cells. Furthermore, they found 
hypomethylation without evidence of overexpression of interferon-regulated genes, suggesting 
strongly that naïve CD4+ T cells in SLE are primed for a rapid type-I interferon regulated gene 
expression upon stimulation. Their data demonstrated that the majority of hypomethylated genes 
in naïve CD4+ T cells in SLE are interferon-regulated. Additionally they identified hypermethylation 
of two genes known to be SLE genetic susceptibility loci (CD247 and IL21R). This would suggest 
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that epigenetics is an alternate mechanism that may disrupt these genes in human SLE. These 
findings highlight the ability of epigenetic mechanisms to modulate the genetic risk of SLE (105, 
106). However it is not clear how this genome-wide hypomethylation phenotype develops initially, 
but multiple studies have identified novel mechanisms that may play a role (105, 106).  
 
Taken together it can be seen that epigenetic differences is not only linked to but is thought to 
cause SLE pathology - this is achieved via disruptions to the methylation machineries. However 
how the genome-wide methylation initially occurs isn't known. The literature also highlighted naïve 
CD4+ T cells as an appropriate candidate cell type for methylation analysis. 
 
1.4.2.2 Sjogren’s syndrome 
Epigenetic mechanisms have been long been known to be involved in Sjogren’s syndrome. Similar 
to other autoimmune diseases, DNA methylation in SS circulating immune cells is generally 
reduced. Similar to SLE, the CD70 gene has been demonstrated as hypomethylated and 
overexpressed in SS CD4+ T cells (107). Furthermore, one would expect that the population of 
regulatory T cells (Tregs) in SS would be reduced with disease progression. This is seen to be the 
case, as CD4+FOXP3+ T cells are reduced, due to hypermethylation and reduced expression of 
the FOXP3 gene (108) 
A genome-wide DNA methylation study was conducted in naïve CD4+CD45RA+ T cells in 
comparison to HCs. 553 CpGs were found to be differentially methylated. 64% of these CpGs 
were hypomethylated. Several genes of interest were differentially methylated such as 
lymphotoxin α (LTα), which is a particularly interesting finding, as LTα is overexpressed in both 
salivary gland tissue and sera of SS patients. Furthermore, it is upregulated in the salivary glands 
of SS murine models, and if LTα is knocked out in these same murine models they don’t develop 
SS (109). 
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Several genes involved in type I interferon pathway were also found to be differentially methylated, 
including STAT1, IFITM1, IFI44L, and USP18 – these findings were similar to those in the above 
SLE study. A gene in particular which had significance was the RUNX1 gene which is particularly 
important in T cell development, was found to be hypermethylated among SS patients. In addition, 
The T-cell receptor ζ-chain gene CD247 was hypomethylated, which highlights the importance of T 
cell signalling in SS (110). 
Again, like SLE, SS also appears to be correlated with epigenetically changed genes which control 
and effect methylation levels. Furthermore containing differentially methylated genes which 
upregulate the immune system seems to be characteristic of SS.  
 
1.4.2.3 Systemic sclerosis 
T cell dysfunction is closely related to the development of SSc, just like SLE. This is particularly so 
in early disease, where the autoreactive T cells transfer signals to surrounding fibroblasts leading 
to collagen deposits and fibrosis (111). Also like SLE, it appears that hypomethylation of CD4+ T 
cells, is also driven, at least in part, by the downregulation of DNMTs. Therefore contributing 
significantly to the overexpression of various genes important to disease pathology (111). 
 
The CD40L gene is found to be hypomethylated in SSc. In addition to its role as an adaptive 
immunity costimulatory molecule, a study has shown that CD40L plays a major role in the fibrosis 
of SSc (112,113). Furthermore, CD40 is found to be overexpressed in fibroblasts of SSc patients 
(114,115), and that blockade of the CD40L/CD40 interaction can reduce fibrosis in SSc murine 
models (116). Also similar to other autoimmune diseases, CD70 is hypomethylated and its 
transcript overexpressed in CD4+ T cells from SSc patients (117, 118). 
 
In contrast to immune cells, the expression of DNMT1 is significantly increased in dermal 
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fibroblasts of SSc patients (119). Fibroblasts play a key role in SSc pathogenesis, particularly in 
organ and skin sclerosis where collagen is overproduced as well as other extracellular matrix 
components. 
A genome-wide methylation assay was conducted examining large-scale differential methylation 
patterns in dermal fibroblasts taken from patients with different subtypes of SSc (120) Only 203 
CpG sites were consistently methylated among the two SSc subtypes.  Furthermore, the majority 
of these differentially methylated CpG sites were hypomethylated. This is despite the 
aforementioned studies showing an increase in DNMT1 expression (121) 
Among the CpG sites that were shared, several were located on collagen genes, such as COL4A2 
and COL23A1, or collagen breakdown enzymes. Among the SSc subsets, there was further 
hypomethylation of COL6A3, COL1A1, and COL12A1 in one subset and COL16A1, COL8A1, and 
COL29A1I in another. In addition, the transcription factors RUNX1 and RUNX2, which have also 
been associated with eroded cartilage in osteoarthritis and RUNX3, a T cell-associated 
transcription factor, were all hypomethylated in both SSc subtypes (121, 122). 
 
Again, similar mechanisms to the other auto-immune conditions seem to appear. SSc is 
associated with epigenetic changes which effect the epigenetic methylation machineries, and the 
activity of immune cells. In addition, SSc seems to also possess disease-specific epigenetic 
changes, in the example of SSc this is likely highlighted by the changes to the 'COL' genes which 








1.4.2.4 Rheumatoid arthritis 
RA is perhaps best described as the prototype chronic inflammatory disease with features of 
autoimmunity (123).Even so, the first RA methylation studies showed that patients’ T cells show a 
remarkably similar phenotype to SLE, characterised by genome-wide hypomethylation (123,124). 
Subsequent studies confirmed this, but did not find evidence for association between methylation 
levels and disease activity or DNMTs and disease activity; furthermore, it was found that the best 
therapeutic agents, TNF inhibitors, did not alter the methylome in PBMCs from RA. Indicating that 
changing the levels of TNF, a prime effector of RA pathology, had no effect on the differential 
methylation found in PBMCs from RA patients (125). 
The development of larger DNA methylation assays have allowed for more unbiased evaluations 
of DNA methylation levels from a genome-wide perspective. Despite this, most studies have to 
date looked only at mixed cell populations such as PBMCs. So considering the specificity of 
methylation marks to particular cell types, it is therefore unsurprising that these data have not yet 
revealed significant differences between RA patients and controls.  
DNA methylations pattern similar to that found in SLE have been found in candidate gene studies, 
wherein female RA patients have demethylation of the immune costimulator CD40L, which is not 
found in male RA patients, perhaps offering insight into the female predominance of the disease. 
However more study is needed in this area to deduce anything concrete (126). 
A recent study did provide insights into the interaction of the RA PBMC epigenome and the 
underlying genomic code. This study identified ten DNA methylation phenotypes that appeared to 
mediate the underlying genetic risk for RA, with nine being within the major histone compatibility 
(MHC) complex, previously significantly implicated in RA in multiple genetic polymorphism studies 
(127). 
A much stronger differential methylation has been found in synovium and synoviocytes from RA. 
Early candidate gene studies identified hypomethylation of elements that drive the expression of 
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MAP kinase, which in turn creates an aggressive cartilage-breakdown phenotype in RA fibroblast-
like synoviocytes (FLS) (128,129). 
It was also found that the maintenance methyltransferase, DNMT1, is downregulated in RA 
synovial fibroblasts (130). The subsequent findings supported similar findings in other autoimmune 
conditions regarding DNMT1 downregulation. They showed that there was a repression of 
machinery responsible for producing the methyl donor required for DNA methylation (131).  
Further studies indicated that there was chronic immune stimulation by IL1, TNF, or toll-like 
receptor ligands in various combinations in vitro which in turn mediated effective suppression of 
DNA methyltransferases (131-133). 
 
Taken together, it can be seen that RA, like all the other auto-immune conditions listed here have 
epigenetic changes to their methylation machineries, they also possess epigenetic changes which 
encourage T cell activity. Furthermore, each autoimmune disease appears to possess epigenetic 
changes to genes which are unique to their given pathology and likely contribute towards their 











1.5.1 Choosing a candidate cell-type 
From this it can be seen that there is precedence of epigenetic aberration being involved in RA, 
however there do appear to be gaps in the published epigenetic RA studies. For instance, as 
previously mentioned, previous studies investigating epigenetics in RA have typically looked at 
PBMCs and not individual populations within the PBMC population. As a result investigating 
individual epigenetics of pathologically relevant cell types within the PBMC population would be a 
viable study model.  
 
In such a study individual cell types should be focused on, as attempting to look at the entire 
PBMC population's epigenetic mosaic is disadvantageous as it assumes that the cell types within 
this population will all develop the same epigenetic aberration. Furthermore, as previously 
mentioned, the proportions of different cell subtypes can be better or worse represented in PBMC 
blood in RA patients. Not only might there be differences between RA patients, but the epigenetic 
data would favour the cells with the greater populations and would poorly represent the 
populations fewer in number - even if they have significant epigenetic aberration. As a result, for 
more reliable epigenetic data, a relevant cell type needs to be selected and isolated from PBMCs 
for an epigenetic investigation into RA.  
 
PBMCs contain T cells, B cells, NK cells and monocytes. All of these have a role in RA pathology 
and are all potentially suitable for an epigenetic study.  All of these are potentially suitable as, in 
addition to the several studies outlined above investigating epigenetic aberrations in RA T cells, 
literature suggests that WBCs in RA patients have increased telomere shortening in comparison to 
HC. Though literature does indicates that this shortening does appear independent of disease 
severity or duration. This telomere shortening is also found in early RA patients, specifically within 
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T cells. This telomere shortening is an indicator of cellular age (132). As previously mentioned, 
ageing is a key factor in the formation of epigenetic abnormalities. It is therefore likely that WBCs 
who endure advanced ageing develop abnormal epigenetic mosaics. 
The candidate cell type should therefore be able to be found in PBMC samples, an individual cell 
type with a sufficiently large population to be analysed and relevant to the RA pathology. Whilst all 
PBMC cell types have a role within RA pathology, of these cell populations CD4+ T cells arguably 
has a more important role due to their role in attracting and directing immune response elements 
during inflammation. This role is a critical one within the setting of a chronic autoimmune disease 
such as RA as they are involved in maintaining the chronic inflammatory response. As a result 
CD4+ T cells has been appropriately selected as the candidate cell type for this epigenetic study.  
 
 
1.5.2 Aims and Objectives 
The aim of this study is to verify the data found in the previous Illumina 450k methylation array 
which suggests that RA CD4+ T cells are differentially and significantly methylated in comparison 
to healthy controls.  
 
 This objectives of this study will be to:  
 Identify an RA-relevant candidate gene from the Illumina 450k methylation array data  
 Bisulphite sequence the candidate gene in CD4+ T cells - in both RA and HC patients. 
 Analyse the sequenced candidate gene, in RA and HC, to derive methylation levels.  
 Determine if the candidate gene is differentially and significantly methylated in RA CD4+ T 
cells in comparison to HC CD4+ T cells. 
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1.5.3 Hypothesis  
H1: My hypothesis is that the candidate gene identified in CD4+ T cells will be significantly 
differentially methylated in RA patients in comparison to HC (p≤0.01).  
 
H0: My null hypothesis is that the candidate gene identified in CD4+ T cells are not significantly 
differentially methylated in RA in comparison to HC (p>0.01). 
 
This hypothesis will be tested by identifying a candidate gene from the data produced by a 
previously performed Illumina 450k methylation profile assay; which was done on isolated PBMC 
RA and HC CD4+ T cells. In order to identify a candidate gene with this data, statistical tests and 
ranking parameters will be employed to shortlist significantly hyper or hypomethylated genes. The 
most hyper or hypomethylated significant genes will then be reviewed by literature analysis to 
determine which may possess the greatest influence in RA pathology. Once a candidate gene has 
been chosen, an appropriate region within the gene shall be chosen to analyse which region 
would likely impart an effect on its transcription if differentially methylated – likely the promoter 
region. This area would be analysed by bisulphite sequencing and data from which would 
determine if the CpGs within are similarly methylated to what was found within the methylation 
profile data. If verified that the candidate gene region is differentially methylated, then it will be 
investigated how this might impact the CD4+ T cell and its role in RA pathology via a literature 
review of the gene's pathway and its various interactions it facilitates.  





2. Materials and Methods 
 
2.1 Ethics and IACON 
The inflammatory arthritis disease continuum longitudinal study (IACON) obtains immunological 
data from the analysis of histological, serum and blood samples, and therapeutic response data and 
correlates it with clinical information from inflammatory arthritis patients. The cohorts have previously 
been used in identification of non-responder subtypes and analysing the pathophysiology of 
remission in RA patients. This study was ethically approved (see appendix 7.1) and conducted under 
the IACON study number 09/H1307/98. 
 
2.2 Isolation by negative selection of CD4 T-cells from PBMCs 
The CD4 T-cells were isolated with the Human CD4+ T cell enrichment kit (STEMCELL, UK). The 
cells were diluted if the numbers were greater than 4.25x108.  The ‘cocktail’ solution (100 µL) was 
added to the sample and suspension was incubated for 10 min at room temperature (RT). Next 50 
µL of the magnetic bead solution was added and was left to incubate for 5 minutes at RT. Sample 
volume was increased up to 5ml with the recommended medium (PBS + 2%FBS + 1mM EDTA). 
The tube was placed in the EasySepTM magnet at RT for 5 min. Without shaking, in one motion, 
the magnet and tube were inverted and the solution was transferred into a clean 15ml falcon tube. 
After centrifugation at 5,000 RCF for 5 min at 4°C the supernatant was discarded, and the cell 






2.3 CD4+ purity check 
The purity of the isolated CD4 T-cells was then checked for each sample. Purity was assessed 
using flow cytometry method. First, 10 µL of the isolated cell suspension was placed in a flow tube. 
Then 2 µL of the antibody mix composed of: CD3 FITC, CD4 V500 and CD8 A700 antibodies were 
added (BD Biosciences, USA). This solution was incubated for 30 min at RT. Finally 100 µL of cell 
fix buffer was added. Stained cells were acquired using a flow cytometer (BD FACSCanto, BD 
Biosciences, USA). The CD4 T-cells subset was considered pure at the level of 90% and DNA was 
subsequently extracted for future analysis.  .  
 
2.4 DNA extraction 
The DNA from CD4 T-cell’s was extracted with the QIAamp DNA blood mini kit (QIAamp DNA 
blood mini kit, QIAGEN, UK). First, 20 µl of QIAGEN proteinase K, at a concentration of 100 
µg/mL, was added to an Eppendorf tube followed by 200µL of cell suspension. 200 µL buffer AL 
was added and vortexed before incubating the samples at 56 °C for 10 min. After incubation, 200 
µL of 100% ethanol was added, vortexed and briefly centrifuged to pull all the liquid to the bottom 
of the tube. The solution was placed in a QIAGEN MINI spin column and was centrifuged at 
6,000g for 1 min; then the filtrate was discarded. The spin column was placed in a clean collection 
tube before adding 500 µL of the AW1 buffer. The column was centrifuged again at 6,000g for 1 
min, filtrate was discarded and, column placed in clean collection tube followed by 500 µL of the 
AW2 buffer added before centrifugation at 20,000g for 3 min. Additional centrifugation for 1 min at 
20,000g was performed. The column was placed in a clean 1.5ml Eppendorf tube and incubated 
with 200μl of elution buffer at RT for 5 min, then centrifuged at 6,000g for 1 min. The DNA 
concentration and quality was measured using The Nano Drop (ND-1000, Labtech International, 
UK) to determine whether samples were of a sufficient quantity. 
 
33 
2.5 Bisulphite conversion treatment 
In order to observe the methylated CpG site the extracted DNA was bisulphite converted. The EZ 
DNA methylation-GoldTM kit, Zymo Research, USA kit was used. First the conversion reagent () 
was prepared of 900μl of nuclease-free water, 300μl M-Dilution Buffer, and 50μl M-dissolving 
Buffer in a CT conversion reagent tube. The 130 µL of conversion reagent was added to 20 µL of 
DNA sample in a PCR tube. Usually between 200 and 500 ng of DNA was converted. The sample 
was placed in a thermal cycler (TC-512 Gradient Thermal Cycler, Fisher Scientific, UK) , with a 10 
min cycle at 98 ° C, then 64 ° C for 2.5 hours. Converted DNA was then cleaned up using column 
method and 600 µL of M binding buffer. The sample on the column was centrifuged at 10,000g for 
30 sec before adding 100 µL of wash buffer and centrifuging again at 10,000g for 30 sec. The 
desulphonation buffer was then added, incubated for 20 mins at RT and subsequently washed 2 
times with 200 µL of washing buffer and centrifuged at 10,000g for 30 sec. After that, the column 
was placed in a 1.5 ml microcentrifuge tube, and 10 µL of elution buffer was added, it was 
centrifuged at 10,000g for 30 sec resulting in  10 µL of bisulphite converted DNA.  
 
 
2.6 Gene amplification 
A single polymerase chain reaction (PCR) had a total volume of 20 µL which consisted of: 10 µL of 
Master Mix, 0.1 µL total volume of forward and reverse primers, 0.8 µL of 25mM MgCl2, 7.1 µL of 
nuclease-free water, and 2 µL of DNA sample (HotStarTaq DNA Polymerase, QIAGEN, UK). The 
primers were at an initial concentration of 500nM (Thermofisher Scientific, USA). 
 
The PCR program contained 40 cycles of denaturation, annealing and elongation can be seen 
below in Table 1. 
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Table 1: The optimised parameters of the thermal cycler for PCR. 
  Temperature (° C) Time 
Initial denaturation 94 15 min 
Denaturation 94 10 seconds 
Annealing Primer specific 30 seconds 
Elongation 72 60 seconds 
Final maintenance 15  ∞ 
 
Amplified PCR product was detected on a 1.5% agarose gel in the presence of 10% ethidium 
bromide alongside hyperladder 1kb (Bioline, USA) to determine the correct size of the product. 
The gel was run for 1 hour at 100V. The gel was then viewed using a Gel Doc™ XR+ Gel 
Documentation System (BioRad, UK).  
 
2.7 Sequencing 
The PCR product was then sequenced. First 2.5 µL of PCR product was added to a PCR plate 
with 1 µL of ExoProStar enzyme (IllustraTM ExoProStarTM, GE Healthcare, UK). The solution was 
then placed in the thermocycler for 1 cycle of: 15 min at 37°C, 15 minutes at 80°C, then held at 
15°C. The 3.5 µL of nuclease-free water was added to each well and was mixed with 0,25 µL of 
“Ready Reaction Mix” and 3.5 µL of sequencing buffer, 4.25 µL of nuclease-free water, and 1 µL of 
1.6µM forward or reverse primer depending on whether the forward or reverse sequence is being 
sequenced, respectively.  The plate was then run on the thermocycler for 28 cycles of: 96°C for 
10 sec, 50°C for 5 sec,  60°C for 4 min and was then held at  4°C. 
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In preparation for sequencing the sample was precipitated with ethanol. To each sample 1 µl of 
‘3M sodium acetate pH 4.6’ and 25 µL 95% ethanol were added and incubated for 30 min at RT. 
After incubation the samples were centrifuged for 30 min at 2254g. 
To dry the subsequent pellet the plate was inverted on a tissue and was centrifuged at 185g for 1 
min. Then 70 µL of 70% ethanol was added and centrifuged at 1650g for 15 min at 4°C. The pellet 
was again inverted on a tissue and was centrifuged at 185g for 1 min. The pellet was then dried 
for 1 minute at 95 ° C on a thermocycler. After drying the pellets were re-suspended in 20 µL of 
HiDi formamide. The samples were then ready for sequencing on the 3130xl Genetic Analyzer 
(ABI Prism, USA). 
 
2.8 Software Analysis 
2.8.1 Sequencing analysis 
The raw data was then analysed by the Sequencing Analysis software 5.3.1 (Applied Biosciences, 
USA). This software produced a graph of signal strength of the nucleotides at all the positions on 
the DNA strand it was reading from 5' to 3'. The resultant DNA sequences were then aligned with 
the expected bisulphite sequence by using the Basic Local Alignment Search Tool (NCBI, USA) 
which showed where the 8 CpGs fell on the read DNA sequence. From the graph of the relative 
nucleotides the T and C signal peak heights were measured and what percentage was C signal 
was derived, the greater the C percentage the more methylated the CpG. From here, using this 
methodology, HC and RA patient DNA was sequenced multiple times and had their CpGs read 





2.8.2 Initial gene selection and primer design 
A candidate gene is selected from the methylation profile data based upon how differentially 
methylated it is - both in regards to significance of the methylation and also the number of CpGs 
that are significantly differentially methylated. In addition, the gene must have some clinical 
relevance to the pathology in question – in this instance, RA. 
 
Once a candidate gene has been selected it must have primers designed for it. However bisulphite 
sequencing restricts the use of PCR products longer than ~350bp, so multiple primer pairs are 
needed in order to properly sequence all the CpGs in a given gene. The candidate gene had its 
sequence found from the UCSC human genome database (www.genome.ucsc.edu). This 
sequence was then placed through a Zymo online bisulphite converter tool at 
(www.zymoresearch.eu) which converted the sequence into its bisulphite equivalent. The 
bisulphite sequence then had primers designed around fitting as many CpGs in a PCR product. 
The primers had to be between 25-30 bp long and have a similar Tm value.  
Once a set of primers have been successfully designed they had to have their PCR conditions 
optimised. This was done by using temperature gradients on the thermocycler and also having an 
MgCl2 concentration gradient. By doing so the optimum temperature and MgCl2 concentration were 
found for each primer set. The primers were then sequenced on HeLa DNA, the sequenced product 








3.  RESULTS 
3.1 DNA Methylation data  
DNA Methylation profiling was performed on CD4+ T-cell DNA extracted from 4 healthy controls 
(HC) and 10 RA patients using an llumina 450K Array. The data was analysed for difference in DNA 
methylation levels for over 450,000 CpGs across the whole genome initially by myself. I first filtered 
the raw data by significance (p≤1x10-2), then I divided the data by chromosome. From here I 
analysed which significant CpGs were within 1 nucleosome of each other (250bp). I now could look 
at which genes had the most amount of clustered highly significant differentially methylated genes 
and rank them. This revealed 55 genes with 374 CpGs significantly differentially methylated, 162 
CpGs were hypermethylated and 211 CpGs were p≤10-3. In order to highlight clusters of these CpGs 
they were ranked by distance from the next CpG. 100bp, 250bp and 500bp were used as distances 
ranked highest to lowest respectively. CpGs separated by ≤100bp were highlighted green, between 
100bp and 250bp highlighted yellow and between 250bp and 500bp were highlighted red. Then the 
CpGs with their ‘cluster rankings’ were lined up with their respective genes and those genes were 
ranked on a table by number of greens, number of consecutive greens, number of colours, number 
of consecutive colours. It was decided to rank the overall list by number of consecutive greens as 
this was thought to more likely to carry over a transcriptional effect. The list was then divided by 
‘Less methylated’ and ‘More methylated’. This wording was chosen carefully as some genes on the 
list had CpGs that were both hypo and hypermethylated, so if there were more hypo than hyper it 
would be classed as less methylated - and vice versa. Fortunately, the genes were often greatly or 
completely polarised toward methylation or hypomethylation, however I felt the distinction was 
important. It should be noted that there weren’t any cases of having equal amounts of both 
methylated and unmethylated CpGs within a gene. The results for this process can be found in 
appendix 7.2. 
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In order to verify my top ranked genes I got a PhD student in the group, Miss Rujiraporn Pitaksalee 
to perform some computational analysis using R-programming software. She showed 648 genes 
with significantly differentially methylated CpGs (p≤1x10-3). Of these 648 genes, 354 were 
hypermethylated and 294 were hypomethylated. They were ranked on how significantly and 
differentially methylated they were in comparison to HC. Her results were more inclusive than mine 
however the top hypomethylated genes were highly similar with B3GALT4, TNF, DAXX and CUTA 
being in the top 5 hypomethylated genes for both analyses. The top 15 hypermethylated and 
hypomethylated from the PhD student’s analysis can be seen in Table 3. My ranking method and 
















Table 2: Showing the study number, age, gender and DAS28CRP scores of the 9 RA patients used 
in the verification study. DAS28CRP is a measure of RA disease activity with a score of <2.3 
indicates remission, 2.3-2.7 means a low disease activity 2.7-4.1 means a moderate disease activity, 
and 4.1< is a high disease activity score.   
IACON Age Gender DAS28CRP 
147 74 F 3.29 
384 55 F 5.11 
444 33 M 2.7 
510 65 M 3.39 
520 40 F 5.72 
612 62 M 4.56 
762 44 F 2.81 
879 62 F 3.32 
1190 51 M 4.08 
Literature analysis showed that 3 genes in the top 10 ranked hypomethylated genes and 1 






Table 3: showing in descending order the most significant 15 hypo and hypermethylated genes in 






















According to literature searches, the other top 28 genes have various functions, some seemingly 
unrelated to RA pathology although the gene OCSTAMP could also be related to RA as it is involved 
in osteoclast differentiation. Two genes, ABAT and CUTA are involved in the metabolism of 
neurotransmitters (134,135). A number of genes are found to be associated with cancer; HIC1 is a 
gene that is found to be hypermethylated in cancer cells (136). HPN is associated with prostate 
cancer, and MAZ is found to be deleted in colorectal cancer (137). B3GALT4 and BAALC are found 
to be associated with lipid raft formation (138). A lot of the genes found in this list are those that are 
associated with proper embryonic development: HMX2, RNF32, HOXB-AS3, CELF4, MEOX1 (139). 
 
All 16 top ranked hyper and hypomethylated genes were run through a gene network analysis 
program (Genemania).The software analysis generated a diagram showing the various types of 
interactions these genes may have with each other (Figure 1). The definitions of the genes 






Figure 1. Gene network of the top 14 hypomethylated genes from the methylation profiling assay 
(circles with the grey stripes). The blue lines indicate that the genes share a pathway and the 





Out of the hyper and hypomethylated genes, only the hypomethlyated gene network showed 
presence of any significant associations (Figure 1).The hypermethylated gene network showed 
very limited links (data not shown).  
 
The 14 genes show that the only hypomethylated genes that are related by a shared pathway is 
DAXX and TNF. Also a lot of the 14 genes are coexpressed with one another and some that aren't 
directly coexpressed share coexpression with a secondary gene which isn't necessarily 
hypomethylated. 
 
The software program also searches which functions the list of genes is likely involved in; then it 
attaches a Q-value for significance. This analysis suggested that the list of the top 15 differentially 
methylated genes in early RA is likely to be involved in positive regulation of JUN kinase activity, 
MAP kinase activity and the regulation of stress-activated protein kinase signalling cascade.  
 
 
3.1.1 TNF signalling cascade analysis  
The gene network map suggested that the TNF gene is involved in several associations and in the 
significant functions highlighted (regulation of MAP kinase activity and the regulation of stress-
activated protein kinase signalling cascade).  In addition, TNF is placed highly on the ranked list of 
significantly differentially methylated genes (3rd place) and so are others genes involved in its 
signalling cascade. As a result this project was focused on the TNF cascade. I reconstructed the 
TNF-alpha signalling cascade as shown in Figure 2, and identified around 65 proteins that are 
involved step-by-step in the cascade from TNF itself to its membrane receptor, the kinases and 
signalling molecules to the transcription factors and genes whose transcriptional regulation is 
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directly related to TNF-signalling. 
 
 
I then investigated DNA methylation pattern individually for each gene. As can be seen from Figure 
2, 14 of the proteins/genes (TNF, DAXX, CD30, CD160, LIGHT, NIK, MAP3K14-AS1, BCL2, UACA, 
TRAF1, TRAF5, TRAF6, ZAP70, KSR1) directly or indirectly involved in the TNF cascade, were 
differentially methylated however, with lower p-values (p≤0.01) compared to the TNF gene (p≤ 
0.001), hence not at the top of the original list. To clarify genes stated to be indirectly involved in the 
TNF cascade are genes whose translated proteins share and contribute to the same downstream 
effects as the TNF cascade - such as NFkB activation. These NFkB-activating parallel pathways 











Figure 2. The TNF pathway 13 hypomethylated genes and 3 
hypermethylated genes. In total 16 differentially methylated genesare 
involved in the TNF cascade in RA.a) showing the caspase apoptotic 
cascade, b) showing CD30 NFkB activation, c) TNFRSF14 stimulation 
of NIK via LTBR, d) RANK induction of NIK via a TRAF complex, and e) 
TCR induction of ERK2. 
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As can be seen from Figure 2, some of these genes are key elements of the TNF cascade. In the 
TNFR1-related apoptotic cascade, 4 genes are differently methylated; 4 genes are differently 
methylated in the TNF cascade; 1 genes that effect transcription; 9 genes involved in parallel 
pathways and are also differently methylated. This indicates that the epigenetic mosaic doesn't just 
effect one aspect of one signalling pathway, but multiple aspects and multiple parallel signalling 
pathways. The shared function of the majority of these pathways is NFkB activation.   
 
Considering the TNF gene significance of methylation and relevance in RA it was therefore chosen 
as a candidate gene for direct bisulphite sequencing to confirm the differential DNA methylation 
data between HC and RA patients. The gene structure is described in Figure 3a. This gene does 
not have a defined CpG island but has several CpG rich regions spread through-out the gene. The 
CpG interrogated by the array are highlighted on the Figure 3b and the differential methylation 
levels observed between HC and RA patients are also depicted in Figure 3c. 
 
 3.2 Primer design 
The TNF gene was found to have 14 CpGs that were significantly differentially methylated in RA 
compared to HC (Figure 3c). These CpGs were dispersed through the gene and as a result multiple 
PCR products were needed in order to be able to sequence these regions to validate the difference 
in methylation levels. As a result 6 primer pairs were designed to amplify 6 regions, hence 6 PCR 
products, based on the bisulphite converted DNA.  All 6 products are shown in relation to the TNF 




Various factors were taken into account when designing primers. The primary factor to be kept in 
Figure 3: Diagram showing the TNF gene (a) in relation to where the CpGs are 
on the gene (b) and their corresponding methylation level according to the 
methylation profile array data (c). 
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mind is the melting temperature (Tm) of the primers. Typically the ideal range for primers is 52oC 
to 58oC; primers which have Tms exceeding 65oC have a tendency towards secondary annealing 
during the extension phase of the PCR reaction. The Tm of a primer is a function of its length and 
its nucleotide composition therefore the longer the primer the higher the Tm and the higher the GC 
ratio the higher the Tm. Considering that, the ideal primer length is 18-30bp, primers based on 
bisulphite converted DNA tend to be long in order to compensate for the relative lack of Cs in 
bisulphite converted DNA. 
A second factor to be considered is the distance from desired CpGs as the first 25bps of the 
sequence is usually of lower quality, hence CpGs to be tested should be ~25bps or more away 
from primers (i.e. “buffer zone”). 
The final consideration is the desired product length with the recommended range being 150-
300bps. When taking into account the primers and the ‘buffer zone’ required, the region that can 
be sequenced is approximately 40-190bp.  
Following these criteria, the TNF gene was divided up into 6 suitable regions, each associated with 
a primer pair. Each resulting PCR product was numbered 1 to 6 from the 5’ to 3’ of the gene (Figure 
3a); and the primer pairs associated with each products shared the same numbering system.  
The process of primer design is illustrated on Figure 4. First a target DNA sequence to sequence is 
identified which contains desired CpGs; the bisulphite converted DNA sequence is then established 
in silico (using Zymo bisuphite conversion software) and from this converted sequence, primers are 
designed. As previously mentioned both primers need to be 25bp or longer and 25bp or more away 
from the desired CpGs. In addition the Tms of the forward and reverse primers must be within 1ºC 
of each other to ensure proper melting and annealing during PCR amplification. To verify the Tm of 
my primers I used Primer express software. Once the primers are positioned they should produce 












Following the above procedure for designing primers and PCR products, I identified 6 suitable 
regions in the TNF gene, for each of which I designed primers for a PCR product. The sequence of 
each primer pair sets is provided in appendix 7.3. 
 
 
3.2.1 PCR optimisation 
To optimise the amplification of my 6 PCR products, I proceeded to use a standard temperature 
gradient and in addition used a variable concentration gradient of MgCl2.   
As an example, Figure 5a shows that primer pair 3 generated the same amount of PCR products 
across the temperature range from 56°C to 60°C. It was also stable across the MgCl2 concentration 
range of 1.0-2.0mM. This demonstrated a good, stable and efficient amplification of this PCR product 
3. 
 
In contrast, primer-set 2 (Figure 5b) was put through a similar PCR optimisation with a temperature 
gradient, ranging from 54°C to 58°C. An increase in the amount of PCR product is apparent as the 
temperature increases. This demonstrates how a 1-2 degree difference in temperature may affect 
annealing (despite the Tm being predicted to be 56°C.) and how the efficiency of the PCR reaction 
can be reduced. All 6 products were then optimised and final conditions are described in Figure 5d. 
 
Finally, in Figure 5c each PCR products (1, 2, 3, 4, 5 and 6) were run alongside each other at their 
optimum conditions. It can be noted that even after optimisation products 4, 5 and 6 seem to produce 
secondary products of lower length. However for products 4 and 5, these secondary bands were 
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lower than the 100 bp ladder implying that they are likely to be primer dimers. For product 6 the 
secondary PCR product is much longer and likely to be the secondary amplification of an unknown 





Figure 5: Diagram showing PCR product optimisation. 5a shows 
primer 3 temperature and MgCl2 gradient, 5b shows primer 2's 
temperature and MgCl2 gradient, 5c shows all 6 final optimised 
PCR products, and 5d shows all 6 primer pairs and their optimal 
PCR temperature and MgCl2 concentrations. 
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3.3 DNA Sequencing 
I proceeded to the sequencing of all 6 products using HeLa DNA first to optimize the technique. After 
optimisation of the sequencing reaction and the acquisition of sequences for all 6 products, I aligned 
my sequences and compared them against the theoretical product expected from HeLa DNA. All 
products aligned to the expected sequence however, the quality of the alignment was not equivalent 
for all products, the worse being the longest one and product 6 due to contaminating product.  
It was found that product 3 appeared to provide the most robust sequence. Based on alignment and 
location of the product in relation to the promoter region of the TNF gene, as well as the amount of 
DNA needed per reaction being greatly demanding, it was decided to focus the sequencing in HC 
and RA patients on product 3 only. This product contains 8 CpG sites of which 4 were directly 
interrogated on the Illumina array, and 1 (CpG1) of which was found to be significantly 
hypomethylated by the illumine array. Though it should be noted that all 4 would be considered 
significantly methylated in the initial experiment if p≤3x10-2 was used instead of p≤1x10-2. So whilst 
demonstrating a degree of significance the 3 other probes didn’t meet the critical limit imposed on 
this analysis.  
 
Figure 6a illustrates the beginning of a good quality sequence shortly after the primer, while there is 
a reduction of quality as the read of the sequence reaches the middle of the product. This is what is 
expected and is why the targeted CpGs are positioned 25bp or more away from the primers. This 
sequence also shows single peaks at position where a single C, A, T or G is expected while where 
a CpG site is located, two peaks (2 bases) can be read: T and C this is illustrating the difference in 






Figure 6: a) Showing how the CpG methylation levels 
were calculated, and b) demonstrating what a poor 
sequenced DNA product looks like. 
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Figure 6b shows the reads resulting of sequencing product 6, which was contaminated with a 
secondary product. As can be seen it is not showing single peaks for most of the sequence like it 
does for product 3 (as seen in Figure 6a). This is because the two products possess different 
nucleotide sequences at any given position and both are being sequenced.  
 
The levels of methylation in the 8 CpGs contained in PCR product 3 were analysed by sequencing 
the region in HeLa cells, 8 HCs and 9 RA patients (RA demographics above in Table 2). Their relative 
C and T signals were measured as the average of sequencing results obtained at each position – 
each sample having being repeated a minimum of 6 times. The percentage of the total signal made 
up for cytosine at each of the CpG position in the TNF gene product 3 is shown in Figure 7. 
 
In HeLa cells DNA of each of the 8 CpG was fully methylated in all individually repeated sequencing 
reactions (n=7). For HC (n=9, x̅ =10.7 reactions per sample) DNA methylation of CpGs 1 to 7 on 
average shows variable levels of methylation in the range of  43%-51%, with CpG 3 being the most 
methylated, then CpGs 8 show methylation decreases to 35.95% on average.  
The observed trend is similar but different in RA patients (n=9, x̅ = 8.78 reactions per sample), where 
CpGs 1 to 6 are in the range of 9%-18%, then dropping down to almost 0% methylation for CpG 7 
and a slight rise to 1.55% for CpG 8. Like HC, RA demonstrates a peak at CpG 3 and a general 
decline in methylation from CpG 3 to CpG 8.  
 
Assuming the data in Figure 7 is representative of HC and RA populations and that RA patients once 
had HC methylation levels prior to RA onset then it can be deduced that CpG 7 is the most sensitive 
to demethylation and CpG 4 is the most resistant, based upon reduction in CpG methylation from 
HC to RA.  
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From the results in Figure 7 and Table 4, it can be seen that the CpGs 1 to 7 are significantly 
(p<0.001) hypomethylated in RA patients in comparison to HC. CpG 8 is conclusively 
hypomethylated and does demonstrates some degree of significance however it is orders less so 
(p= 0.01368) than the other CpGs. This difference in CpG 8 is likely due to possessing 1 fewer HC 
to plug into the significance test and possessing a larger variance – both of these factors are likely 
caused by CpG 8 being at the end of the sequence and thus possessing lower quality sequence 
data than the other CpGs. As a result this confirms the data obtained in the Illumina array suggesting 
hypomethylation in RA, for the 1 probe (CpG 1) located in product 3 of the TNF gene (Figure 8). The 
4 probes are the CpGs 1, 5, 7 and 8, found below in Figure 7. For further reference, CpGs 1, 5, 7 
and 8 seen in Figure 7 are cg11484872, cg21370522, cg01569083 and cg03037030, respectively, 







Table 4. P-values demonstrating the significance of the RA and HC methylation at each individual 
CpG outlined in Fig 7. P-values were derived from a Welch’s T test.  
TNF CpG  CpG1 CpG2 CpG3 CpG4 CpG5 CpG6 CpG7 CpG8 
P-Value <0.0001 <0.0001 0.0003 0.0002 <0.0001 0.0002 0.0006 0.01329 
 
 
Figure 7: Diagram showing the pie chart averages of each RA and HC 
patient's  8 CpG methylation levels, and the percentage average of the RA 
and HC's CpG methylation levels.The blue section indicates the proportion of 
cells which are methylated at the CpG shown. Orange indicates the 






Figure 8. The methylation levels of HC and RA CD4+ T cells in the initial Illumina methylation 
profile data (HC1 and RA1) in comparison with the methlyation data (HCv and RAv) of the RA and 
HC CD4+ T cells in this verification experiment at the 4 CpGs picked up by the original Illumina 
array. Cg11484872, cg21370522, cg01569083 and cg03037030 (aka CpG1, CpG 5 CpG 7 and 
CpG 8, respectively. For reference cg11484872 was the probe used to confirm the veracity of the 










4    Discussion 
 
4.1 Candidate Gene Selection 
For a gene to be considered as a candidate it will have to be highly ranked in regards to its degree 
of methylation or demethylation, it will have to have some relevance to the pathology of RA, and it 
should preferably be relevant to the role of CD4+ T cells. 
The TNF gene has been found to be significantly hypomethylated in a methylation profile assay 
(Figure 3 and Figure 7). Furthermore, as will be explained below, it can be seen the TNF is 
responsible for initiating various cascades which cause inflammation and drive the pathogenesis 
of RA. Additionally, considering the relevance of the inflammatory pathway to CD4+ T cells it can 
be seen that the TNF gene is also relevant here too. Due to it satisfying all the outlined criteria the 
TNF gene has been chosen as a candidate. 
 
4.1.1. Demonstrating TNF's Relevance in RA pathology 
TNF was first elucidated as being involved with RA when a research group found that it and 
various other cytokines were being continuously produced in the synovium when usually cytokine 
production should be a transient occurrence. This dysregulation was further investigated by 
extracting cells from the synovium, culturing them and over the course of a week investigating any 
cytokine dysregulation. By using neutralising antibodies specific for certain cytokines they were 
able to deduce a pro-inflammatory hierarchy; they found that antibodies targeting TNF inhibited 
the production of all the other cytokines. It was this discovery that demonstrate that TNF was the 
apex pro-inflammatory cytokine and that TNF was involved in RA (140-145). 
60 
Out of this the first anti-TNF drug was produced – infliximab. Infliximab produced significant clinical 
effects in treating RA; importantly that its effects were long-lasting. This conclusively tied the 
pathogenesis to TNF. Clinical trials demonstrated that clinical improvements could be made better 
by taking methotrexate (MTX) as well. Subsequent studies into TNF elucidated its pathways (140-
145). 
 
4.1.2. NFkB activation of the TNF-dependant cytokine cascade in RA 
TNF has been identified as the prime initiator of the cytokine cascade that is associated with in the 
inflammation-response seen in the pathology of RA. However a 2002 study indicated that although 
neutralising TNF reduces joint-damage in RA, TNF itself does not directly cause the joint damage; 
instead the cytokines and their pathways that it commands.  
 
TNF produces these cytokines by activating NFkB activation via the TNF cascade (147). NFkB 
activation results in the initiation of the TNF-dependent cytokine cascade, which is critical in the 
formation of the inflammation and subsequent damages seen in the pathology of RA. The TNF-
dependent cascade elucidated via anti-TNF drug development is complex and involves several 
cytokines namely: TNF, IL1, IL6 and GM-CSF (148). Specifically, TNF induces an intracellular 
cascade, via interacting with TNFR1, which typically culminates in the activation of NFkB – NFkB 
then stimulates the production of IL1, IL6 and GM-CSF. Here we will discuss here how IL1, IL6 








4.1.2.1 Interleukin 1 
IL1 is a family of 11 cytokines, 7 of which are pro-inflammatory, 3 are receptor antagonists and 1 
which is anti-inflammatory. Although it is distinctly different from TNF there is a lot of overlap; both 
TNF and IL1 stimulate IL6, IL2 receptors, colony stimulating factors and acute phase proteins as a 
result both are effective pro-inflammatory cytokines. IL1 is stimulated via NFkB transcription which 
can be initiated by TNF.  There is a body of evidence to suggest that IL1 contributes to the 
pathogenesis of RA. For example two members of the IL1 family, IL1α and IL1β, when activated, 
act as powerful pro-inflammatory cytokines. They trigger localised vasodilatation and attract 
monocytes and neutrophils to sites of tissue damage and stress. 
Importantly, these cytokines are prime inducers of matrix enzymes and thus serve as powerful 
mediators of tissue damage by changing both cartilage and bone homeostasis. Uncontrolled IL1 
activation is a primary factor of some inflammatory diseases and has been directly linked to RA 
pathology. This has been demonstrated in vivo where IL1β overexpression in rabbit’s knee joints 
results in arthritis with clinical and histological symptoms of RA (149). 
 
4.1.2.2 Interleukin 6 
IL6 is responsible for stimulating B cells to produce immunoglobulins (Ig). In RA, antibodies 
towards citrullinated peptides and IgM and IgG rheumatoid factors are typically increased.  IL6 
does this by stimulating B cells to differentiate into plasma cells which in turn produce said Igs. 
The significance of this B cell activity in RA pathology is evident due to clinical improvement seen 
when B cells are depleted. IL6 is also involved in T cell proliferation and differentiation, specifically 
into TH17 cells. These TH17 cell produce IL17 which in turn can stimulate further IL6 production, 
and increase neutrophil migration by stimulating IL8 (147, 148). This process in human models is 
usually done in combination with IL1 β and IL23. Taking IL6’s significant involvement in the 
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development in the adaptive immune response it can be seen how it may be involved in the 
pathogenesis of RA. 
A hallmark of RA is the presence of chronic inflammation. There is evidence to suggest that IL-6 is 
involved in the shift from acute inflammation to chronic. IL6 is directly involved in activation of 
neutrophils which in turn migrate to tissues and release reactive oxidative species (ROS) and 
proteolytic enzymes which results in tissue damage – in RA this would be seen as joint damage. 
Neutrophils release soluble IL6R when they’ve reached the inflammation site; this causes 
recruitment of leukocytes via activation of adjacent epithelial cells which in turn release pro-
inflammatory chemokines.  
There is a correlation between matrix metalloprotinases’ (MMPs) expression and articular cartilage 
damage in RA; this is due to overexpression of MMPs from cells lining the synovium. In early RA 
patients there is a correlation between levels of C-reactive protein (CRP), IL6 and pro-MMP3; 
indicating a relationship between MMP activity and IL6 (147,148). 
Another manner through which IL6 can contribute towards joint damage in RA is through its 
interaction with vascular endothelial growth factor (VEGF). VEGF is a key mediator and promoter 
of the migration and proliferation of endothelial cells; it also increases local vascular permeability 
and inflammation. IL6 increases the levels of VEGF in the presence of sIL6R; VEGF levels are 
also positively correlated with RA disease activity.  
The narrowing of joint-space and erosions are key characteristics of joint damage in RA. 
Osteoclasts are the cells that play a primary role in the erosions in RA, and IL6 has been shown to 
increase osteoclast recruitment by interacting with haematopoietic stem cells. A study 
demonstrated that IL6 deficient murine models with antigen-induced arthritis (AIA) had fewer 
osteoclasts at the bone erosion sites and a reduced severity of arthritis in comparison to wild-type 
(147,148). 
The most convincing piece of evidence that IL6 is involved in RA pathology is that it was found that 
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neutralising IL6 results in clinical improvement. The drug, tocilizumab, which is an anti-IL-6R mAb, 
was given to RA patients who had a non-responder to one or more disease-modifying rheumatic 
drug (DMARD) demonstrated significant clinical improvement of disease activity within 1 week of 
monotherapy; this improvement held up until week 8. Later, larger trials demonstrated that these 
improvements could be sustained with repeat dosages. In addition it was found that combination 
therapy with MTX improved efficacy of the treatment, this was demonstrated through both 
symptom amelioration and reduction in joint damage (147,148). 
 
4.1.2.3 Granulocyte-macrophage colony-stimulating factor 
GM-CSF is a haemopoeitic growth factor but also modifies the functions of myeloid cells. For 
instance, GM-CSF can polarise macrophages into M1-like macrophages which in turn produce a 
variety of cytokines such as TNF, IL6, IL12p70, and IL23. On the other hand, neutralisation of 
GM-CSF results in the favouring of the formation M2-like macrophages which instead produce 
anti-inflammatory cytokines (150)  
When you then take into account that pro-inflammatory cytokines such as TNF, IL1 and IL23 have 
been found to stimulate the production of GM-CSF and that GM-CSF is found in high levels in the 
synovium of RA patients. It is plausible to suggest that GM-CSF could propagate and sustain the 
pro-inflammatory cytokine cascade through polarisation of macrophages. (151) 
In fact there is evidence to support the position that not only is GM-CSF involved in RA pathology 
but in some circumstances it can be the prime pro-inflammatory cytokine. As it was found that 
severe inflammatory arthritis can be caused by GM-CSF overexpression without TNF 
overexpression. This was further highlighted in RA patients who didn’t respond to anti-TNF drugs 
but did respond well to anti-GM-CSF drugs (MOR103 and Namilumab) (152).  
Taken together it can be seen how TNF is capable of causing damage in RA without being directly 
involved in the damage process via NFkB activation. In addition, if NFkB is TNFs means of 
64 
implementing damage than other pathways which also stimulate NFkB should be considered. 
4.1.3 Other potential gene candidates 
Other considerations aside from TNF, are B3GALT4 and ABI3. Though B3GALT4 is the highest 
ranked gene in terms of differential methylation it doesn’t appear to have any published specific 
relevance in RA. Furthermore the same can be said for ABI3, though ranked highly and possess 
the highest number of coexpressed genes (data not shown) there doesn’t appear to be any 
published data linking it the RA pathology. Based on this, TNF is the superior choice for a 
candidate gene. 
 
4.2 Candidate Gene Region Selection 
Due to the limitations of bisulphite sequencing, the TNF gene which is 4.7kb long and possessed 
24 significant CpGs (see appendix 7.2). This region which encompassed all 24 CpGs was divided 
into 6 regions for individual analysis. Out of the 6 regions only one was to be chosen as the 
candidate region. Based upon the sequencing data of the 6 primer products, products 4, 5 and 6 
proved to be poor candidates and as a result they were omitted from further analysis. One of the 
main reasons thought to be behind these yielding poor sequencing data is the presence of repeat 
nucleotide sequences (as seen in Figure 7). These repeated thymine nucleotide sequences, when 
exceeding 11 repeats disrupt the sequencing data by introducing contractions or extensions. The 
further above 11 repeats these sequences were, the more contractions or extensions will be 
introduced (153).  
This appears to be the reason for why products 4 and 5 are poor candidates as they have very 
long nucleotide repeats (up to 15 nucleotides). However product 6 had the same amount of 
repeats as product 2, which was found to give a good sequence. Therefore it is unlikely product 
6’s poor sequence data is due to a nucleotide repeat sequence. The answer may lie in Figure 6c. 
It can be seen that primer product 6 has a very strong secondary band occurring beneath the 
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desired product’s band. It is likely this strong secondary product is due to the primers binding 
elsewhere on the DNA yielding a shorter product. It should also be noted that the product 
sequences containing nucleotide repeats of 10 or more (2, 4 and 5) have faint secondary products 
occurring below the desired products. Based upon their position and their length they look like 
primer dimers. 
 
Primer products 1, 2 and 3 all provided very good sequencing data in regards to alignment and 
coverage with their expected products. Out of these three, primer product 3 was chosen as it 
contained more significant CpGs than 1 and 2, and also it is located in the promoter region of the 
gene (see Figure 3); implying that any epigenetic modifications in this region would have a larger 
effect on transcription than the other primer products designed, and thus would be more desirable 
to analyse as it would be more likely to contribute towards RA pathology. So, in summation, the 
promoter region of the TNF gene was chosen to be sequenced to confirm the veracity of the 












4.3 Confirming the Candidate Gene's Veracity 
The methylation profiling assay interrogated 4 CpGs in the candidate region and showed 1 CpG 
significantly hypomethylated (p≤1x10-2) in the TNF gene candidate region. However, the 
bisulphite-DNA Sanger sequencing conducted for confirmation showed that 7 out of 8 CpGs were 
significantly hypomethylated. This discrepancy isn’t due to differences in methylation levels, but 
instead to differences in sensitivities, the methylation profiling assay was only able to analyse 4 
CpGs maximum in the candidate region. The CpGs that were shared in this region in both 
methodologies both demonstrated significant hypomethylation in comparison to HC. 
 
We can be confident that the results we have are veracious as the CpGs examined are 
significantly hypomethylated in comparison to HC data. Furthermore the results draw the same 
conclusions as those found previously in the data acquired by using a different methodology. The 
point of using a different methodology for confirmation is to rule out data-influencing factors which 
may be present in one methodology. 
 
Now it has been asserted that the results we have are reliable, it should be discussed their 
relevance and meaning in the pathology of RA. However, inferences from this data should be 
carefully drawn as the confirmation of methylation level from the first assay doesn’t confirm the 
entire dataset of the methylation profiling assay. It only confirms that the TNF gene is significantly 
hypomethylated in comparison to HC in the 1 CpG in the region analysed. That said, the region 
that the 7 hypomethylated CpGs are located in is the promoter region of the TNF gene, therefore 
the hypomethylation of the region is likely to impart a larger effect upon its ability to be transcribed 
in comparison to other CpG regions. 
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4.4 Variance of TNF methylation 
As can be seen in Figure 7 there is a natural variation to the degree of methylation of CpGs in the 
TNF promoter region – both in HC and RA. However across all CpGs RA methylation is lower than 
HC. Variance is a common occurrence in nature and so to see some variance in both HC and RA 
populations is to be expected. Furthermore, such variance could aid in determining whether there 
is a healthy reference range of TNF methylation. Whilst such a determination would likely require a 
larger sample size and a better consideration of potentially confounding factors, such as disease 
severity, age and drug treatments. It can be seen from the pie charts in Figure 7 that the 
methylation level of the CpGs in RA patients rarely rises above 25%, furthermore the HC CpG 
methylation levels rarely drop below 25%. From this it can be said, crudely at least, that a TNF 
promoter CpG methylation level below 25% in the CD4+ T cell population is characteristic of RA. 
Now whether this 25% is the threshold which can predispose a healthy person to RA can't be 












4.5 The TNF cascade 
4.5.1 The TNF receptors 
The members of the TNF ligand family demonstrate their functions by interacting with their 
complementary membrane receptors, these receptors make up the TNF receptor (TNFR) family 
(154).  Two receptors, TNF receptor type 1 (TNFR1) and TNF receptor type (TNFR2) bind to the 
soluble TNF (sTNF), membrane-bound TNF (mTNF) and Lymphotoxin α (LTα). (155) TNFR1 is 
ubiquitously expressed in most tissues, whereas expression of TNFR2 is highly regulated and is 
typically found in cells of the immune system. In the majority of cells, TNFR1 appears to be the 
prime mediator of TNF-signalling, however in lymphocytes TNFR2 seems to play a major role 
(155); though due to the fact that TNFR2 can only be fully activated by mTNF its efficacy is often 
overlooked. The cause for TNFR2 only being able to be activated by mTNF is not fully understood 
but the different binding affinities of the individual ligand-receptor complexes may be a reason 
(155). 
 
As well as being mediators of the TNF pathway TNFR1 and TNFR2 also have the ability to be 
inhibitors as their extracellular domains can be proteolytically cleaved, yielding soluble receptor 
fragments which have the capacity to neutralise TNF molecules (154). That said, the binding 
affinity of the soluble receptor fragments to TNF molecules is not as strong in comparison to their 
membrane-integrated forms.  
TNF possesses a dichotomous functionality. On one hand it has the capacity to induce apoptosis 
but on the other it can also stimulate cell proliferation and survival pathways. One way the TNF 
ligand can induce different functions is dependent upon which of the TNF receptors it binds to. For 
instance due to the fact that TNFR2 doesn’t possess a death domain and TNFR1 does then the 
choice for TNF-induced cell survival can be potentially made at this point in the pathway.  
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The other point is when TNFR1 is stimulated, as it can stimulate two pathways. TNFR1 activation 
can either stimulate cell death, or inflammation and cell survival. It is able to achieve this functional 
versatility by being able to interact with several complexes (Complex I, Complex IIa, Complex IIb 
and Complex IIc). The mechanism behind this live-or-die decision isn’t well understood. It is 
thought that the levels of c-FLIPL and RIPK1 are vital components to this decision. c-FLIPL acts 
as an inhibitor of caspase-mediated apoptosis by binding to Caspase-8 and blocking its function.  
RIPK1 is thought to be ubiquitinated and tied to complex I. However, if the RIPK1 has its ubiquitin 
removed, it gets trafficked to and interacts with apoptotic machinery (156, 157). 
One example of this dichotomous function of TNF in vivo can be seen in liver cells, as liver 
regeneration after partial hepatectomy in TNFR1-deficient models, hepatocyte DNA synthesis is 
impaired, indicating that TNF signalling through TNFR1 is involved in liver regeneration (158). In 
contrast to this, in models of acute hepatotoxicity TNF acting via TNFR1 appears as a key player 
in liver destruction (159). This destructive capability is largely due to its powerful pro-inflammatory 
and immune-stimulatory functions. As a result TNF is a key mediator of progression in many 
autoimmune diseases. Such examples of TNF-involved autoimmune diseases are rheumatoid 
arthritis and Crohn's disease. TNF involvement is demonstrated in these diseases as significant 
clinical improvements can be achieved when patients are treated with TNF-neutralising agents 
(160,161). 
 
4.5.2 Downstream effects of TNF-TNFR signalling 
The downstream non-apoptotic cascade after TNFR1 activation involves the activation of P38 and 
JNK by MAP3K5 and MAP4K5 kinase pathways. The other part involves the phosphorylation of 
the IKK complex, specifically the IKKβ subunit. This results in the dissociation of the NFkB-IkBα 
complex and allows NFkB to translocate into the nucleus. The TNF-TNFR2 interaction activates 
NFkB-Inducing Kinase (NIK) that causes in the same dissociation of the NFkB-IkBα complex and 
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subsequent NFkB translocation. The canonical and non-canonical TNF pathways are outlined in 
Figure 9. 
 
Figure 9. TNF pathway showing how TNF can either initiate pro-apoptotic or proliferative signalling 
via TNFR signalling molecules.  
 
 
4.5.2.1 P38  
P38 is known to mediate the response to cellular stress factors such as osmotic shock and UV 
light. To date, five isoforms of p38 MAPK have been identified. The p38 family can be divided into 
two groups, p38α/β/β2 and p38γ/δ, based on their ability to respond to different stimuli (162). P38 
contributes to the process of leukocyte recruitment by activation of several processes: selectin-
mediated rolling, integrin activation, diapedesis of leukocytes towards an injury site and activation 
of the effector functions in leukocytes.  
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Selectin-mediated rolling is the first step in leukocyte extravasion; this process is requires the cell 
to have adhesion that allows rolling along vessel walls. This temporary adhesion is provided by a 
family of adhesion molecules called ‘selectins’ (L-, E- and P selectins). L-selectins are the typically 
expressed selectin on the surface of leukocytes, and E- and P-selectins are usually expressed 
upon the surfaces of endothelial cells and also have the role of aiding leukocytic adhesion 
(163,164). 
 
After rolling, and their destination reached, a stronger adhesion force is required between the 
endothelium and leukocytes. This firmer adhesion is produced by the binding of β1 and β2 
integrins on the leukocytes to intracellular adhesion molecule 1 (ICAM1) and vascular cell 
adhesion molecule 1 (VCAM1). Once firmly binded to the vessel wall, the leukocyte migrates 
throughout the intracellular junctions between the endothelial cells following a gradient of 
chemokines to reach the site of injury. The type of chemokines produced by an injury site can 
attract specific subsets of leukocytes. For instance in COPD, the cytokines produced attracts an 
influx of neutrophils, whilst in asthma the cytokines attract a predominantly macrophage population 
(162).  
 
Several studies have demonstrated that a p38 MAPK-specific inhibitor can initiate NFkB-
dependent transcription (165, 167). However, phosphorylation of the NFkB subunits, nuclear 
translocation and DNA binding of NFkB were not affected by this p38 inhibitor. This suggests that 
NFkB and p38 MAPK are activated by separate effector pathways, which might converge further 





4.5.2.2 c-Jun N-terminal kinases  
The mammalian c-Jun N-terminal kinase (JNK) was initially called stress activated protein kinase 
(SAPK) because they were activated by a variety of environmental stresses (168,169). Later, the 
JNK pathway was also discovered to be activated by TNF, IL1 and other growth factors. JNK is 
involved in several physiological and pathological processes. Specific stimuli trigger the activation 
of MAP3Ks, which then phosphorylate and activate the MAP2K isoforms MKK4 and MKK7, which 
in turn phosphorylate and activate JNK (149). JNK was discovered to phosphorylate c-Jun at the 
NH2-terminal Ser63 and 73 residues, and thus termed JNK. In addition to c-Jun, JNK can 
phosphorylate transcription factors such as JunB, JunD, c-fos, ATF2 and ATF3 (168,169).  These 
transcription factors along with c-Jun, make up the Activator Protein-1 transcription factor (AP-1), 
which regulates the expression of several stress-responsive genes. The JNK class of enzymes 
comprises of three main types: JNK1, JNK2, and JNK3 (169, 170). The first two are ubiquitous, 
whereas the third is restricted to the brain, heart and testis. Differential splicing and exon usage 
results in multiple isoforms of JNK1, 2 and 3 genes. The alternative forms of each JNK1, 2, and 3 
appear to differ in their ability of bind and phosphorylate different substrate proteins. Targeted 
gene disruption of each JNK has also defined differential functions for JNK1, JNK2 and JNK3 in 
many different cell types. JNK1 or JNK2 deletion resulted in defective T cell activation and 
differentiation (170,172). 
JNK, by phosphorylation, modifies the activity of several proteins that are located at the 
mitochondria or perform roles in the nucleus. JNK is capable of activating and inhibiting various 
downstream molecules. Through JNK, TNF can regulate several cellular functions including, 
differentiation, cell growth, survival and apoptosis through the activation and inhibition of other 





4.5.2.3 NFkB pathway 
The canonical nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) pathway has 
been defined primarily in response to TNF and IL1 signalling, NFkB activation is also widely 
implicated in inflammatory diseases such as RA, inflammatory bowel disease, asthma, and 
chronic obstructive pulmonary disease (173-177). Consequently much attention has become 
focused on the development of anti-inflammatory drugs targeting NFkB (178). 
NFκB activity at sites of inflammation is associated with activation of the TNF canonical pathway 
and Rel-containing complexes. There have been several studies to show proinflammatory cytokine 
and chemokine production by disease tissue is NFkB-dependent; for example, using fibroblast-like 
synoviocytes from RA patients (179,180). 
There has also been correlation of NFkB activation with inflammatory disease in animal models of 
arthritis (181). That said, it is clear from genetic experiments in mice that NFkB activation is not 
necessarily proinflammatory and has complex roles in the inflammatory response. The role of RelA 
as a critical component of the canonical pathway has been demonstrated with the development of 
RelA and IKKβ knockout mice (182, 183). 
A 2001 study showed the involvement of NFkB in both the onset and resolution of acute 
inflammation in a single model system using pharmacological inhibitors (180). Studies have 
confirmed the expected role of NFkB in proinflammatory gene-induction during the onset of 
inflammation but also showed a putative role for NFkB in the expression of anti-inflammatory 
genes and in the induction of leukocyte apoptosis during the resolution of inflammation. Also these 
studies suggest an anti-inflammatory role for NFkB that limits the bactericidal and tumouricidal 
function of macrophages (180-184). 
Gene knockout studies have also shown that NFkB subunit proteins can have both pro- and anti-
inflammatory roles. For example, homodimers of the p50 subunit of NFkB, which lack 
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transactivation domains, have been shown to repress expression of NFkB target genes and inhibit 
inflammation (185). An anti-inflammatory role of NFkB was also demonstrated in inflammatory 
bowel disease in which “p50−/−p65+/− ” murine models were more susceptible to H. hepaticus-
induced colitis (186-187). As a result study data suggests that NF-kB can have an anti-
inflammatory role, as well as an inflammatory role, by directly inhibiting expression of 
proinflammatory genes and by manipulating the expression or activity of anti-inflammatory 
cytokines such as IL10 (188). These multiple roles can be seen in T cells as NFkB can help T cells 
avoid glucocorticoid-mediated apoptosis during positive selection. Whilst on the other hand, NFkB 
has the opposite role in mature peripheral T cells, promoting apoptosis by increasing FasL 
expression, which may be linked to the termination of T cell responses (189). 
4.5.2.4 Non-canonical activation of NFkB 
The alternative NFκB pathway is characterised by the inducible phosphorylation of NFkB2 by 
IKKα, leading to activation of RelB/NFkB2 heterodimers. The upstream kinase that activates IKKα 
in this pathway has been identified as an NFkB-inducing kinase (NIK). 
Recent studies suggest that IKKα has evolved distinct, but possibly complementary, roles in 
adaptive immunity and inflammation. IKKα functions to promote the resolution of inflammation by 
switching off the canonical NFkB pathway (176), and regulates the development of adaptive 
immunity through the alternative NFkB pathway (189,190). Although inflammation is classically 
considered to prime the adaptive response, the resolution of inflammation is also required to avoid 
tissue injury while supporting the development of the immunological memory. Cross-talk between 
the alternative and canonical NFkB pathways may regulate the transition from acute inflammation 
to antigen-specific immune responses that drive autoimmune diseases such as RA and multiple 
sclerosis. It is thought that, inhibition of IKKα may represent a therapeutic target to prevent 




4.5.3 TNF cascade-related methylation aberrations in RA CD4+ T cells. 
Now the key elements of the TNF cascade have been introduced, the aberrations found in the 
methylation levels of elements directly and indirectly involved in the TNF cascade should be 
analysed. This is a relevant area to investigate as any significant differences in methylation levels 
of downstream effectors likely highlight differences in the regulation of the TNF pathway and/or 
NFkB activation. It should be noted that data indicating hypomethylated genes alone doesn't 
indicate a tangible increase in the translation of a gene, it merely shows that the gene is primed 
and more ready for transcription. As a result the following analysis of the TNF cascade is simply in 
order to highlight aspects and elements which could be better or worse primed for transcription 
(Figure 2). 
 
4.5.3.1 Inhibition of NFkB with DAXX and TRAF1 
The apoptotic pathway is available to TNF due to TNFR1 having a death domain (TRADD), which 
in turn can interact with DAXX and in turn initiate a caspase cascade. However in this scenario it is 
possible that DAXX’s up-regulated inhibits the TNF cascade, in conjunction with TRAF1, and not 
necessarily for the 'purpose' of initiating apoptosis (192). 
As seen in (Figure 2a) FAS-associated DAXX initiates the caspase cascade by interaction with 
FADD-interaction. Now, FADD can then initiate the activation of caspase 8 who in turn can activate 
tBID or can also enzymatically interact with TRAF1. Caspase 8 cleavage of TRAF1 results in a 
product which inhibits the formation of IKKb dissociation and subsequent NFkB activation. 
A 1998 study showed that NfkB activation blocks the activation of caspase 8 and its subsequent 
caspase cascade. The study noted that TRAF1, TRAF2, c-IAP1 and c-IAP2 were all required to 
fully block TNF-induced apoptosis. However the methylation data only indicates that TRAF1 is 
differentially methylated and not the others highlighted in this study. That said even if all were 
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hypomethylation, it wouldn't prove they are all being translated. (193). 
 
Regardless, only TRAF1 being primed for transcription highlights either the greater complexities of 
transcriptional regulation or that TRAF1 can inhibit via another process. Whether caspase 8 
interacts with TRAF1 or BID likely depends on their availability and as a result, an upregulated 
TRAF1 inhibiting caspase 8 via competitive inhibition could very well be a means to ensure this.  
 
However, caspase 8's interaction with TRAF1 can still contribute towards a pro-apoptotic signal, 
likely through NfkB deactivation, for instance a 2003 study demonstrated in carcinoma cells that 
TRAF1 cleavage is an indicator of chemo-induced apoptotic signalling. However this pathogenesis 
isn't known for chronic NFkB activation as found in RA. So therefore TRAF1 cleavage wouldn't be 
as inducing of apoptosis in RA due to relatively higher level of NFkB activation (194). 
Furthermore, it should also be noted that DAXX is also able to inhibit NFkB function directly if it is 
located in the nucleus, further supporting the idea of it possessing functions outside of simple 
apoptotic initiation (194), 
 
More evidence suggests the apoptotic cascade is downregulated due to the presence of 
differentially methylated genes which could act to inhibit the apoptotic caspase cascade. These 
include: hypomethylated BLC-2 which is the inhibitor of t-BID, and inhibits the release of 
cytochrome C from mitochondria; and further downstream a stimulator of apoptosomes is 
hypermethylated, UACA. In summary the methylation data suggests that TRADD-initiation of 
DAXX and caspase 8 could be in order to lessen the activity of NFkB and not necessarily for the 
purpose of apoptotic initiation. 
Whether or not apoptosis or proliferation is being favoured can be demonstrated in this study fairly 
easily. It can reasonably be assumed that RA CD4+ T cells are selecting proliferation over 
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apoptosis due to the presence of a stable, epigenetically distinct cell population. 
4.5.3.2 CD30 
CD30 is a cell-surface receptor whose role is involved with lymphocyte activation and survival; 
CD30 does this through its ability to induce the transcription factor NF-kB (Figure 2b).  In 
contrast, CD30 has also been implicated in the stimulation of apoptotic cell death of lymphocytes 
(195). It has been found that CD30 signal transduction renders cells sensitive to apoptosis induced 
by the TNFR1. However, this sensitisation is dependent on the TRAF-binding sites in the 
cytoplasmic domain of CD30. One of the proteins that binds to these sites is TRAF2. Study data 
suggests a model in which CD30 limits its own ability to transduce cell survival signals through 
reductions of levels of TRAF2 (195). In addition it was found that reduction in levels of intracellular 
TRAF2 and its associated proteins also increased the sensitivity of the cell to apoptosis to death-
causing complexes such as the TRADD-TNFR1 complex. Additionally the study found that, the 
expression of a dominant-negative form of TRAF2 was found to potentiate TNFR1-mediated death 
(195). A potential mechanism has been elucidated, through which CD30, as well as other TRAF-
binding members of the TNFR superfamily, can negatively regulate cell survival. Furthermore 
CD30 signal transduction and concomitant TRAF2 degradation reduces the ability of TNF to 
induce NFkB signalling (195). 
 
As a result hypomethylation might indicate overexpression of CD30. Although CD30 would likely 
be involved in promoting cell survival excessive stimulation of CD30 would result in promotion of 
TNFR1-mediated apoptosis due to TRAF2 depletion. However, as mentioned above, the 
molecules involved in the initiation of the TNFR1-TRADD apoptotic pathway might well be used for 





4.5.3.3 LIGHT/LTα/HVEM role in T-cell activation  
Tumour necrosis factor super family member 14 (LIGHT) and LTα have been identified as herpes 
virus entry mediator (HVEM) ligands, based on their ability to bind to HVEM. As well as HVEM, 
LIGHT was additionally identified as a ligand for LTβR (196). LIGHT expression is more restricted 
and tightly regulated than HVEM with LIGHT mRNA expressed predominantly in the spleen and 
brain with relatively low levels of expression in peripheral blood leukocytes, amongst other sites 
(196-197). LIGHT is upregulated on T cells upon activation and thus is reciprocally expressed 
compared to HVEM which is high on unstimulated T cells, declines after activation and rises 
several days later (196, 198). 
 
The expression of LIGHT on T cells in murine models leads to over-activation and expansion of 
activated T cells, resulting in autoimmune diseases and severe inflammation of the gut (200) which 
correlates with accumulation and activation of DCs (199-201). Murine models deficient in LIGHT 
have a defect in CD8+ T-cell activation and potentially in thymic selection (202-204). 
 
 
LIGHT is directly and indirectly capable of stimulating NFkB and JNK (Figure 2c) which would 
achieve the same function as the TNF-dependant cytokine – stimulating cell survival, cytokine 
production, and proliferation (205-209). Furthermore, not only is LIGHT found to be 
hypomethylated, but so is TRAF5, which is an important associated factor in signal propagation.  
Due to LIGHT being tightly regulated and being specifically upregulated with T cell activation; it is 





4.5.3.4 RANK induction via NIK 
The receptor activator of NFkB’s (RANK) cytoplasmic domain interacts with TRAF2, TRAF5, and 
TRAF6 (Figure 2d). RANK’s overexpression also is found to activate NFkB and JNK pathways.  A 
study demonstrated that TRAF2 and TRAF5 bind to different TRAF binding motifs than TRAF6 
which interacts with a specific motif of RANK. Furthermore, it was found that the TRAF6-binding 
region, but not the TRAF2 or TRAF5-binding region, is necessary and sufficient for RANK-induced 
NFkB activation. It was found that RANK activates NFkB via NIK, as a kinase mutant of NIK 
inhibited RANK-induced NF-kB activation. In regards to JNK activation however, it was determined 
that TRAF2 was more important than TRAF5 or TRAF6 in JNK activation (210). 
RANK-induced propagation of an NFkB and JNK signal is likely to be present in RA CD4+ T cells, 
as TRAF5, TRAF6 and NIK are all involved in this process and all found to be hypomethylated. 
Furthermore, highlighting the importance of TRAF2 in NFkB activation, TRAF2 has been found to 
be an important component in the outlined signalling mechanism. 
 
4.5.3.5 cFOS activation via the TCR 
TNF has been shown to activate Zap70 (Figure 2e). Zap70 has in turn been shown to activate 
linker for activation of T-cells (LAT). T-cell-receptor (TCR)-mediated LAT phosphorylation is crucial 
for the membrane recruitment of signalling complexes required for T-cell activation. Although 
phosphorylation of LAT is needed for recruitment and activation of signalling proteins, the exact 
mechanism associated with this event is not clear (211). 
The signalling pathway mentioned essentially involves LAT forming a complex with RAS which is 
released when activated. RAS can then interact with the KSR1-RAF-MEKK-ERK complex. Which 
releases Erk and in turn stimulates the transcription factor c-FOS – which is a proto-oncogene.  
There does appear to be a route by which TNF can induce c-Fos activation and contribute to cell 
80 
survival other than by inducing NFkB, P38 and JNK. That said the c-Fos activation caused by Erk 
signalling is thought to be quite weak. So any pro-oncogenic effect caused by this mechanism 
would likely be marginal (212). As previously mentioned, ERK signalling could instead be involved 
in the regulation of methylation maintenance machineries, DNMT1, and continue to maintain and 
contribute towards the aberrant epigenetic mosaic. 
 
4.5.3.6 NFkB Signal Modulation 
Overall the differentially methylated pathways appears to be primed to stimulate NFkB and 
consequently support cell survival and proliferation of the CD4+T cell.  
 
On the other hand there seems to be epigenetic modifications that would dampen NFkB activation; 
DAXX-mediated NFkB inhibition can occur either by the caspase 8 cleavage of TRAF1 (Figure 2a) 
or by direct inhibition by DAXX in the nucleus (Figure 2). The former would seem to target the 
canonical TNF cascade directly whilst the latter would target generic NFkB activation.   
 
Further evidence for NFkB inhibition lies in the fact that there is a dampening of genes responsible 
for NIK activation. For instance the LTBR gene is hypermethylated, potentially inhibiting LTa or 
LIGHT stimulation of NIK (Figure 2c), and also the antisense RNA version of NIK, MAP3K-AS1 is 








4.6 TNF Gene coexpression network 
Another aspect to analyse is whether the hypomethylated TNF belongs to a gene coexpression 
network and if any members of said network are also hypomethylated. A gene co-expression 
network is a phenomenon where a set of genes are expressed together, across a range of 
conditions. Usually this is to do with these genes being expressed by the same transcriptional 
regulator, functionally related, or are members of the same protein complex or pathway. Gene co-
expression networks are stated to be a powerful approach to accelerate the elucidation of 
molecular mechanisms underlying important biological processes (213).   
 
Considering that TNF can stimulate the production of more TNF, and that TNF is prevalent within 
RA pathology, it can be seen that genes that are coexpressed with TNF that are also 
hypomethylated would be sensitive to transcription in this pathology. As a result it is important to 
consider what effects any genes found to be both coexpressed with TNF and hypomethylated 
would likely have on the cell. TNF was found to be coexpressed with 10 other genes in the top 50 
ranked hypomethylated genes. 
 
4.6.1 LNPEP 
LNPEP is an enzyme that is responsible for cleaving peptide hormones. It has also been 
associated with inflammatory conditions, specifically with psoriasis (214). Interestingly, TNF 
inhibitors are capable of inducing symptoms of psoriasis (215). Whether or not TNF inhibitors have 
an effect on LNPEP expression isn’t known. However studies show that both TNF and LNPEP are 





RPS18 is a subunit of the 40s ribosomal complex which is the largest component of several 
transcription initiation complexes. The orthologue in e.coli of RPS18 is involved in the initiation of 
translation, specifically the initial fMET-tRNA binding. Therefore it is likely that RPS18 is also 
involved in translation initiation and thus is perhaps is a rate limiting step to this process if its 
expression was limited. It is seen that RPS18 is upregulated at the protein level in cancer, this is 
consistent with RPS18’s role as cancer cells tends to have greater transcriptional requirements 
than healthy cells. In CD4+ T cells in RA it has been found that RPS18 is hypomethylated, 
indicating that this cell type has been primed to favour RNA translation (216) 
 
4.6.3 GPSM3 
GPSM3 is a regulator of G protein-coupled receptor signalling, which has its expression restricted 
to leukocytes and lymphoid organs. It has been demonstrated that SNPs in GPSM3’s 
transcriptional start site is inversely correlated with RA. That is that SNPs that reduce the ability of 
GPSM3 to be transcribed provide a protective affect against RA (217) Therefore it is consistent 
with expectations to see that GPSM3 is hypomethylated, and thus primed for transcription, in 
CD4+ T cells from RA patients.  
 
4.6.4 DAXX 
DAXX is a protein responsible for initiating a caspase-mediated cascade which can result in 
apoptosis of a cell. Furthermore DAXX-induced apoptosis can be activated by TNFR1. Therefore 
one might expect that DAXX would be downregulated in order to promote cell survival in CD4+ T 
cells from RA. However it was found that DAXX was significantly hypomethylated in this cell type.  
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Upregulating an apoptotic gene may seem contradictory in considering what has been found so 
far. However it has been found that silencing DAXX can actually sensitise cells to several 
apoptotic mechanisms (241). Furthermore, several studies have found that DAXX may have a 
more complex role and may possess anti-apoptotic functions (242).  Therefore, due to DAXX 
being multi-faceted it is difficult to state what is expected with only methylation data available. 
4.6.5 TLR9 
TLR9 is an important receptor expressed in immune system cells including dendritic cells, 
macrophages, natural killer cells, and other antigen presenting cells.TLR9 is also an important 
factor in autoimmune diseases, so much so that there is active research into synthetic TLR9 
agonists and antagonists that could help regulate autoimmune inflammation (218, 219). It has also 
seen to be overexpressed in RA monocytes (220) and that it has a role to play in the pathogenesis 
of RA (221). As a result it is consistent and expected to see it being hypomethylated in CD4+ T 
cells from RA patients (222). 
4.6.6 ZNF217 
ZNF217 is a zinc finger protein is an oncogenic factor involved in various human cancers. It’s 
amplification and increased copy number has been found to be linked to poor clinical prognosis. 
ZNF217 is so correlated to some cancer pathogeneses that it is being used as a potential 
biomarker and therapeutic target (223). ZNF217 has been found to be able to 
attenuate apoptotic signals resulting from telomere dysfunction and may promote neoplastic 
transformation and later stages of malignancy (223). TNF has been associated with breast cancer 
progression (224). ZNF217 whilst it is part of a HDAC and initial research thought it be involved in 
transcriptional repression. Further research has shown that it regulates specific genes and 
possess a more complex role than generically repressing transcription and is thought to contribute 
to tumorigenesis by dysregulating gene expression programs (225-228). From this it can be seen 
that if ZNF217 is being hypomethylated in CD4+ T cells it is indicative of the cell being primed 
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towards cell survival and proliferation - this strengthens the argument that the RA CD4+ T cells are 
primed for survival instead of apoptosis. 
4.6.7 TMC6 
TMC6 has been implicated in the rare skin disorder epidermodysplasia verruciformis, specifically 
when it possesses inactivating mutations. Although the exact mechanism and significance of this 
phenomenon remain to be determined, it seems probable that changes in nuclear and nucleolar 
zinc concentration could strongly influence function of the cell (229).   
In this study it was found that TMC6 plays a role in the immune response; stimulating antiviral 
factors such as chemokines, cytokines and growth factors. In particular a study showed that the 
proinflammatory cytokine, IL6, was expressed less in knockout experiments. Specifically the 
effects caused are thought to be mediated by JNK and ELK1 activation (229). In addition to 
TMC6’s outlined proinflammatory capacity, zinc influx has been stated to be an ionic signalling 
molecule after T cell activation and is essential for innate and adaptive immune response in 
another study (230). As a result it is understandable that TMC6, a proinflammatory, T cell activator, 
would be hypomethylated in RA CD4+ T cells. 
 
4.6.8 PTPRCAP 
PTPRCAP is a phosphoprotein that is specifically associated with CD45, a surface marker on 
lymphocytes, and has been shown in a study to be a key regulator of both T and B cell activation 
(231). Aberrations to CD45 have been shown to be related to autoimmune conditions (232). In 
addition CD45 deficiency has been linked to SCID (233); it would therefore appear that CD45 
presence is correlated to immune activity. Ergo, in CD4+ T cells in RA one might expect to see 
PTPRCAP, CD45’s associated protein, upregulated. This is what is seen as PTPRCAP is 






CORO1A was found to be a TNF-coexpressed gene that is hypomethylated. In a recent genome-
wide longevity study, CORO1A expression levels were found to be negatively associated both with 
age at the time of blood sample and the survival time after blood draw. It is also thought to be 
involved in mitochondrial-mediated cell death (234), like that initiated by TNFR1 (235) and T cell-
mediated immunity. It mediates T cell activity through its association with CD45 and its regulation 
of intracellular Ca2+ signalling (236). This is the second CD45-related molecule in this CGN, likely 
highlighting CD45 as relevant in RA CD4+ T cells.  
It should be noted that CORO1B and also KCNN4 and KCNC4 encode proteins that are 
involved in Ca2+ signalling – an important component in regulation of T cell activation (237,238). 
Though not coexpressed with TNF - CORO1B and KCNN4 are also hypomethylated. As a result 
the expectations are met that T cells, whom are likely to be more active in a condition such as RA, 




The ABI protein family are primarily known to be involved in regulation of the actin cytoskeleton 
through the formation of a WAVE complex. The family contains three members ABI1, ABI2 and 
ABI3. ABI3 in particular was a later addition to this family and was done so simply on the grounds 
that it possessed amino acid similarity towards the other ABI members. Whilst all three proteins 
share a very similar domain structure, that includes a WAVE-binding (WAB) domain; in comparison 
to ABI1 and ABI2 little is known about the function of ABI3. This is due to the fact that the ABI3-
WAVE complex appears to be functionally different to those ABI-WAVE complexes formed with 
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other ABI family members. The specific differences observed that the ABI3-WAVE2 complex is 
unable to form lamellipodial protrusions in response to fibronectin stimulation. In addition, 
expression of Abi3, but not Abi1 or Abi2, reduced the formation of invadopodia in the v-src- cancer 
cell line, and increased invadopodia formation when cAbl was inhibited. It is through these aspects 
that it can be seen that ABI3 is distinct from other ABI family members (239). 
 
Whilst invasiveness of cells, from the perspective of cancer cells, is seen as a negative thing. In 
the immune system, immune cells need the ability to be able to invade regions of the body to help 
conduct a successful immune response. Invadopodia formation grants a cell the ability to invade 
very difficult places such as the basement membranes that surround tissues. In the context of 
autoimmune conditions, invadapodia-formation is associated with disease progression, as seen in 
RA (240). 
 
As a result one might expect that CD4+ T cells from RA would have ABI3 suppressed – promoting 
cell invasiveness. However it is seen that ABI3 is actually hypomethylated and primed for 
transcription. Now obviously ABI3 could have its transcription regulated downstream, nor might it 
even be pathologically important for CD4+ T cells to possess the ability for aggressive invasion.  
It should be noted that ABI3 is the highest ranked gene in regards to most coexpressed 
hypomethylated genes. As a result it might be that any effect ABI3 could have would be done so 
through the other genes it is co-expressed with – such as TNF.  
It should also be noted that the CD4+T cells potential lack of invasive ability could be down to 
selection bias. As the CD4+ T cells were taken from peripheral blood, one naturally shouldn’t 
expect to find a large proportion of cells which are very invasive as by definition they would have 
or be invading tissue and not be in peripheral blood. It should be therefore considered that the 
CD4+ T cells analysed could be a less-invasive subgroup. Though this can’t be said for certain 
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without further investigation and analysis. 
Taken together it can be seen that the hypomethylated genes in TNF’s CGN are proinflammatory, 
prosurvival, involve molecules which interact with the T cell signalling regulator - CD45, and 
members whose transcription positively correlate with RA pathology. This is consistent with what is 
seen in the published literature and is expected in an autoimmune condition, where the CD4+ T 
cells are active and interact with TNF. It should also be noted that 4 out of the 10 genes listed 
here, TNF, DAXX, LNPEP and GPSM3 are all located in the MHC region. Considering this, 1 of 
the 4 is the candidate gene being analysed, and that the MHC region has been implicated in RA 
pathology (247). A closer look at the MHC region is warranted. 
 
4.7 The broader cause of hypomethylation and the MHC region 
The data from the top 50 hypo- and hypermethylated genes showed via genemania software 
analysis that no significant functional ontologies were found in the hypermethylated group but 
several were in the hypomethylated list. Specifically, it was found that genes involved with MHC 
class I antigen processing, regulation of JNK and positive regulation of NFkB were significantly 
represented (p≤0.05) and therefore the hypomethylated gene network, if transcribed, was 
significantly likely to be involved in promoting said processes. It should be noted that the functional 
ontologies highlighted are not mutually exclusive for instance TNF and DAXX are involved in both 
NFkB and JNK regulation and whilst not in MHC I antigen processing have locis in the MHC 
region.  
In regards to MHC antigen processing, it has been long known to be associated with RA 
pathology. Furthermore it is the only region of the genome that has been consistently shown to be 
associated with RA (247). The MHC region is situated on chromosome 6 and extends over 3.6 Mb. 
It is divided into three regions, classes I, II and III. The class I region, located at the telomeric end 
of the MHC, contains HLA-A, -B and –C, and extends over 2000 kb. In the HLA class II region are 
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the HLA-DR, -DQ and -DP loci. The class III region is located between the class I and II regions. 
The MHC is a highly gene dense region containing around 220 genes, many of which have 
immunoregulatory functions (248) 
The genes said to be connected to MHC class I by the gene network analysis are TAP1, HLA-E 
and LNPEP. Through literature analysis, some genes on the hypomethylated list have also been 
related to the MHC class II region, these genes are: PSMB8, TAP 1, PSMB9, Col11A2, HSD17B8, 
RPS18, B3GALT4, TAPBP, DAXX have all been classed as MHC Class II region genes and all of 
which are significantly hypomethylated in CD4+ T cells in RA. There are also hypomethylated 
genes found in the Class III HLA region these are TNF, DDH2, LSM2, STK19, TNXB, PBX2 and 
GPSM3 (249) This data strongly suggests that, at least at the DNA level, the MHC regions are 
significantly hypomethylated in CD4+ T cells in RA. To further demonstrate the MHC region’s 
significance, out of the top 5 ranked Hypomethylated genes 3 are located in an MHC region as are 
5 in the top 15. Whilst MHC region hypomethylation doesn’t account for all the epigenetic 
aberration seen it is clear that it would explain the large portion of highly hypomethylated, 
seemingly unrelated genes.  
MHC hypomethylation already has been shown to be involved in modulating genetic risk in several 
autoimmune conditions including RA (250, 251). As a result what has been found in this study is 
consistent with what has been found in previous published literature. The hypomethylation of MHC 
region appears particularly relevant in RA CD4+ T cells. This is to do with the fact that the MHC is 
fundamental to the CD4+ T cell's role of antigen recognition and subsequent cytokine signalling to 
other immune cell populations. Epigenetic changes to this region could adversely change the 
regulation of the MHC and therefore the cell's behaviour towards antigens, and as a result could 
contribute towards RA pathology (248-252). However the exact cause of why in particular the 
MHC region is affected and why in particular the TNF gene is hypomethylated is not something 
answerable from this study data. That said through literature review answers might lie in the link 
between coexpression and hypomethylation. 
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4.7.1 The link between coexpression and hypomethylation 
In this study I have highlighted that TNF is hypomethylated, and has a hypomethylated 
coexpression gene network, hypomethylated TNF cascade and peripheral pathway members and 
is located in a hypomethylated DNA (MHC) region. Considering this overlap, in this section I will 
discuss how coexpression networks, gene loci and gene functions are inter-related in regards to 
hypomethylation.  
Coexpression has been linked to colocalisation. That is, genes which are coexpressed often are in 
close proximity to each other. Therefore if a region, such as the MHC region, becomes 
hypomethylated it should be expected that coexpression networks located there become affected 
by said epigenetic changes. (242).  
Also considering that these coexpressed gene networks often share functions and/or are part of a 
pathway, it can be seen how hypomethylation of a coexpression gene network can result in 
pathway members, even in peripheral but functionally-related pathways, demonstrating 
hypomethylation (243). 
 
This link between coexpression and hypomethylation goes further; this is because transcription 
factors, which coexpressed genes networks share, also mediate DNA methylation maintenance 
(244,245). Ergo aberrations or conditions which negatively affect the DNA methylation 
maintenance machinery interacting with particular TFs can in theory predispose coexpressed gene 
networks, which share said transcription factors, to methylation loss (246). 
 
This matches with what we see in this study as regional hypomethylation being the sole cause 
would only explain 4 of the 10 hypomethylated coexpressed genes. So it is clear there is more to it 
than the genes simply being in the same region. It is likely that certain TF or TFs, that this CGN 
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share, have been affected and any regional correlation of CGN genes is due to colocalisation of 
certain coexpressed genes in said network. Though of course this explanation for the 
hypomethylation of TNF’s CGN doesn’t explain the many other hypomethylated genes in the MHC 
region and the rest of the genome. It is probable that the regulation of many other TFs has been 
affected also and is the cause of the epigenetic mosaic seen here - however there needs to be 
further study to investigate this. 
 
I postulate that the MHC region appears particularly central in this data set due to its functional 
importance in CD4+ T cells and its relevance in RA pathology. It is probable that this region would 
be transcriptionally active in RA CD4+ T cells. So it can be seen that either the region is more 
prone to wear and tear, due to increased use, and possesses a lower ability to repair itself due to 
dysfunctional DNMT machinery or RA CD4+ T cells are ‘purposefully’ modifying the MHC region to 
better interact and respond to signals in RA pathology. However none of these postulations can be 
ascertained without thorough further investigation. 
 
 
The epigenetic mosaic observed in RA CD4+ T cells in this study can be generally characterised 
by global and MHC-region hypomethylation and priming of genes which facilitate NFkB interaction. 
Whether said epigenetic mosaic is a cause or consequence of RA is not something that's 
answerable just using the data found in this study. Though it is likely that ageing, environmental 
stressors and genetic and/or epigenetic predispositions are factors that leads to progressive 
genome-wide hypomethylation in CD4+ T cells, and that the hypomethylation of genes in CD4+ T 




In conclusion, it has been confirmed by a different methodology that the TNF promoter region 
analysed is significantly hypomethylated in CD4+ T cells in RA patient’s peripheral blood in 
comparison to HC. The veracity of the CpG highlighted by the earlier methylation array assay has 
been confirmed and has highlighted a further 6 more CpGs that are significantly hypomethylated.  
It has discussed that the many of the highly-ranked hypomethylated genes happen to be in the 
MHC region on chromosome 6, indicating a degree of regional DNA hypomethylation; it has also 
been discussed that the genes TNF is coexpressed with genes that promote T cell activation, 
survival and proliferation; in addition various primed pathways in the TNF cascade have been 
discussed which seem to favour cell survival, proliferation, and inflammation propagation. All of 
which is consistent with what is seen in RA pathology. This verification study has been successful 
and demonstrates that CD4+ T cells are epigenetically distinct in RA in comparison to HC.  












5.0 Limitations and areas of further study 
 
5.1 Limitations of methodology 
Using a different methodology to observe the same phenomenon not only is useful to confirm the 
veracity of the first data set through adding additional data to the data pool, but by using a different 
methodology you show that the methodology specific to producing the first data set wasn’t the 
cause of the phenomenon. However there are various limitations to using the bisulphite DNA 
Sanger sequencing methodology. 
 
A major limiting factor pertains to Sanger sequencing and it being unable to read DNA products 
over the length of 1,000bp. However this problem is compounded when the DNA undergoes 
bisulphite conversion, as converted DNA is unstable above 350bp. As a result not only is the 
length that can be read limited, but the length of bisulphite-converted DNA that can be amplified is 
limited. As a result this methodology is unable to verify all the data found all at once – in fact even 
with one gene this is found to be difficult. 
As a result the short amplified products that result from amplifying bisulphite-converted DNA 
require more primers in order to cover the same sequence in comparison to normal DNA. In 
addition due to more primers there is more area on the DNA that isn’t sequenced very well due to 
proximity to said primers. Getting the primers to be both of an appropriate length and possess high 
enough Tms for successful amplification and sequencing is challenging due to the lack of Cs in the 
DNA. This issue was resolved by finding G-rich areas and or placing an undesired CpG in the first 
third of a primer – both of which ameliorated both primer length and Tm problems. 
 
Not only is primer design an issue but sequencing bisulphite-converted DNA is difficult due to its 
inability to read long nucleotide repeats. Specifically with bisulphite-converted DNA poly-T repeats 
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are common, however only repeats longer than 8 start to affect sequenced product with every 
additional repeat exponentially increasing the risk of a nucleotide expansion or contraction. 
Expansions and contractions occur due to the polymerase slipping during it reading the DNA 
strand. This adversely affects the read sequence as it doesn’t always happen consistently. As a 
result you end up with multiple peaks occurring downstream as the sequence has different 
amounts of repeated nucleotide that have been added. Multiple peaks at a given point are a 
problem for a couple of reasons, firstly the quantification of methylation level become interfered 
with and less accurate if another base is being read at the locus of CpG; also in order to make 
sure that the correct CpGs are being measured at the right location the read sequence gets 
aligned with the expected sequence used to design the primer, this becomes a problem if the 
fewer or additional nucleotides result in the sequence not matching the expected sequence. A 
further problem with poly-T repeats is that the longer the repeat the more likely the polymerase will 
terminate reading the DNA strand, this results in variable length products and thus a degrading 
signal following the poly-T region, this reduces the accuracy of the CpG methylation quantification 
(153,253). 
 
The Sanger sequencing bisulphite conversion methodology is restricted to observing DNA 
methylation. However but also the methodology also is unable to differentiate between modified 
cytosine variants. This is due to the bisulphite conversion process keeping both variants as a 
cytosine and as a result 5mC and 5hmC simply appear as a methylated cytosine in the 
sequencing data. 
 
Modified cytosine variants occur because 5mC can go through sequential oxidation by the ten-
eleven translocation enzyme (TET). TET family enzymes turns 5mC into 5-hydroxymethylcytosine 
(5hmC) and then to 5-carboxylcytosine (5caC) and 5-formylcytosine (5fC), the latter two are 
thymine substrates and are eventually turned back into an unmodified cytosine. Whilst 5hmC is an 
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intermediate in this process it is considered to be a stable epigenetic mark with it making up 1%-
10% of all modified cytosines (254). 5hmC is known to possess distinct epigenetic function as 
studies have shown with genome-wide sequencing maps of various mammalian cells and tissues 
that 5hmC is a marker for gene expression with it being enriched in enhancers, promoters and 
gene bodies, also changes in 5hmC correlate to gene expression levels (255).  
As a result knowing which modified CpG variants are present is important to know if one wishes to 
fully understand the effect of these modifications on a candidate’s DNA and gene’s expression.  
 
Furthermore, the spontaneous deamination of 5mC to thymine isn't something that this 
methodology can pick up on, as these appear simply appear as any other demethylated CpG – a 
thymine. This spontaneous occurrence could be important in understanding the predisposing 
factors which aid the formation of the observed epigenetic mosaic in RA CD4+ T cells, however 
bisulphite sequencing can't detect this as they'd simply appear as unmethylated CpGs.  
 
In addition, this methodology doesn’t quantify actual gene expression of the gene being 
sequenced; as a result whether or not specific cytosine modifications are having any contribution 
to altered gene expression in a specific disease pathology cannot be determined quantitatively 
with this methodology. 
 
There are limitations to the sequencing software used as it isn’t designed for viewing multiple 
peaks at a given position. This is shown through the presence of the phred quality score (Q). This 
Q value is defined as a property that is logarithmically related to base-calling error probabilities, 
that is, the higher the score, the better confidence that can be had in the nucleotide shown at that 
position.  Now considering that multiple peaks at a given point negatively affects the phred quality 
score it can be seen that software’s means of deducing base-calling error and thus quality at a 
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CpG location won’t be very reliable.   Furthermore the software package has no DNA 
methylation- related features which would have assisted in data processing. All the CpGs had to 
be measured individually which was time consuming and labourious. As a result, if this experiment 
were repeated, efforts would be made to find software which facilitates sequenced bisulphite-
converted DNA data processing.      
 
An option available, if repeated again, would be to use pyrosequencing instead of Sanger 
sequencing. The method would allow the use of software packages that deduces the proportion 
Cs and Ts on a CpG at a given position without the need to do it manually. However this method 
doesn’t address limiting factors associated with bisulphite conversion or designing primers for 
amplification, nor does it allow longer DNA products to be used in sequencing.   
 
Another issue is the RA DNA that was used, generally had low DNA concentration in comparison 
to HC DNA concentrations. As a result the bisulphite conversion process had to be modified so 
that the conversion reagent was instead proportional to the concentration of DNA instead of DNA 
volume. That is, a sample with a low concentration of DNA needed more volume to be viable so 
more bisulphite conversion reagent needed to be used to maintain the same concentration 
needed. Despite doing this some of the RA patient’s DNA concentrations were omitted for being 
too low. This low DNA concentration is likely to do with the age of the sample, fortunately despite 
age of a sample influencing DNA yield it doesn’t seem to influence the DNA’s integrity. However in 
future it would be better to use fresher DNA samples in order to get better DNA yields.  
 
It should also be noted that the patient samples were not matched with the ones used in the 
original Illumina methylation array. This was done out of practicality, as samples were selected 
based upon their DNA yield. Due to RA patient’s blood samples being inherently poor, the quality 
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of samples selected was important and was prioritised over any benefits drawn from matching 
samples. Furthermore if the effect is found in RA it should be expected to be seen in other RA 
patients and if it isn’t then it would be down to chance or some idiosyncrasy of the patients in the 
first cohort. As a result using other RA patients to verify the first data was a stronger choice for 
verification as not only does it increase the pool of data confirming the phenomenon but it likely 
rules out any confounding idiosyncratic biases in the first study as the cause of the observed 
epigenetic aberration. 
 
5.2 Future steps 
Now that the promoter region of the TNF gene has been found to be hypomethylated in CD4+ T 
cells in RA patients the next step would be to repeat the experiment but with a larger cohort of 
patients. This would allow better understanding of the range of the hypomethylation of the TNF 
promoter in RA patients in comparison to HC. This is important as it would help to establish if there 
is a healthy range of methylation levels in the TNF promoter region. 
   
Once the epigenetic mosaic occurring in the TNF gene has been better quantified, it would then be 
of interest to see at which point in the pathogenesis of RA that TNF gene undergoes significant 
hypomethylation. It would also be relevant to assess whether the level of TNF promoter 
methylation is associated with disease severity. This would show whether this is something that is 
acquired gradually by CD4+ T cells through the disease course or if significant hypomethylations 
exist in the TNF gene in pre-RA - such as that explained in the outlined cancer stem cell model.   
These points are relevant as if there is a gradual change to methylation levels that correlate with 
RA onset and disease severity then one could use this as an RA diagnostic screening tool. This 
might be advantageous over other diagnostic tools, as it doesn’t require patients to have 
symptoms and it could also include both sero-positive and sero-negative RA patients, which is a 
major limitation of present diagnostic blood tests for RA. 
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A different approach would be to see if there are transcription differences in RA CD4+ T cells in 
comparison to HC. This would confirm whether or not the methylation differences elucidated 
actually carry over any effects on to the transcription of the respective genes.  
This is important to analyse because genes being significantly hypo or hypermethylated doesn’t 
guarantee that they will have their transcription significantly affected. A possible methodology of 
analysing the RA CD4+ T cell transcriptome would be to use gene expression profiling. 
 
Translation is important to also look at; simply because a gene is being transcribed doesn’t mean 
those mRNA transcript products are being translated into a given protein. This is due to 
posttranscriptional modifications such as splicing which can result in different protein variant being 
translated. Furthermore, it should also be considered that translational interference can occur, 
usually via antisense mRNA hybridising with the transcripted mRNA preventing it being translated - 
resulting in gene suppression. Translation analysis can be conducted by looking at the proteome 
of the RA CD4+ T cells. A key methodology used to analyse this would be separation of proteins 
using gel electrophoresis and subsequent identification of proteins by mass spectrometry. 
Another avenue that could be approached would be whether or not TNF is actually being 
transcribed and translated in CD4+ T cells. This could be achieved by looking at the levels of TNF 
mRNA in CD4+ T cells in RA and HC patients. If TNF is being successfully translated and more 
than in HC, and/or at different time points in the pathogenesis of RA, then this could be 
pathogenically relevant. Considering that TNF encourages inflammation and disease progression. 
If found to be true, this could highlight CD4+ T cells being a relevant target for therapy. It should 
also be noted, that even if a gene, such as TNF, is not found to have any transcription or 
translation differences it wouldn’t take away its potential as a diagnostic marker for RA as it’s 
methylation differences are still significant and between RA and HC CD4+ T cells. 
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Fundamentally, analysing the methylome, transcriptome and proteome would give a 
comprehensive gene-activity profile and a better overall picture of what is happening in RA CD4+ 
T cells. Acquiring this data would allow more meaningful conclusions to be made on the role of 
individual genes or groups of genes in RA CD4+ T cells and the role that CD4+ T cells play in the 
pathology of RA. 
 
A further aspect to consider is that CD4+ T cells have subpopulations. Specifically naïve CD4+ T 
cells can differentiate further into: Th1, Th2, Th9, Th17, Th22, Tfh or Tregs. These cell populations 
secrete different cytokines and are responsible for different elements of the inflammation process. 
Further investigation into one or more of these sub-populations is needed to see if their epigenetic 
mosaic differs from each other and in comparison with HC. Considering that the more totipotent a 
cell, the more sensitive it is to epigenetic change, the CD4+ population that should be analysed 
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Figure 10. Raw data from initial methylation array of the TNF gene's CpGs. Row A is CpG probe name, B is 
chromosome position, C is CpG coordinate, D is gene name, E is CpG feature, F is T-statistic, G is difference in mean 
(negative and positive values indicates RA is hypermethylated and hypomethylated, respectively), H is P value, Rows 




























Figure 11. TNF gene CpGs after filtering by (p≤1x10-2). A difference 
column has been added to observe the bp distance between sig 
123 




























Figure 12. Top 15 ranked genes based on proximity of significant differentially methylated CpGs. Red genes are 












Figure 13. Top 15 ranked hypomethylated genes (green), and top 15 ranked hypermethylated genes (red). Listed from 

















7.3 Designed primers and products 
The DNA sequences below show the designed primers and products for the TNF gene. The DNA 
is orientated 5' to 3', the primers are highlighted yellow and the desired significant CpG to be 







 Fwd: 25bp Tm:60.0  











 Fwd: 22bp Tm:55.9 












273 bp Product 
 Fwd: 25bp Tm:58.0 












270 bp product 
 Fwd: 27bp Tm:58.8 















 370bp product 
 Fwd: 25bp Tm: 59.9 











 224 Bp product 
 Fwd: 24bp Tm:59.4 





7.4 Gene definitions 
 
Gene Acronym Gene Name
A20 Tumor necrosis factor, alpha-induced protein 3 
ABAT 4-Aminobutyrate Aminotransferase 
ABI3 ABI Family Member 3 
AP-1 Activator protein 1 
ATF2 Activating transcription factor 2 
B3GALT4
BAALC Brain and Acute Leukemia, Cytoplasmic 
BAIAP2
BAIAP2-AS1
BCL-X1 B-cell lymphoma-extra large 
BCL2 B-cell lymphoma 2 
BFL-A1
BID BH3 interacting-domain death agonist 
BRCA1 Breast Cancer 1
CRel REL proto-oncogene
C myb/c Cancers Myelocytomatosis
CASP 8 CASPASE 8
CD11a
CD160 Cluster of Differentiation 160
CD247 Cluster of Differentiation 247
CD30 Cluster of Differentiation 30
CD40 Cluster of Differentiation 40 Ligand
CD40L Cluster of Differentiation 40 Ligand
CD70 Cluster of Differentiation 70
CELF4 CUG-BP- And ETR-3-Like Factor 4 
COL11A2 Collagen alpha-2 (XI) chain
COL12A Collagen alpha-1 (XII ) chain
COL16A1 Collagen alpha-1(XVI) chain 
COL1A1 Collagen  alpha-1 (I) Chain
COL23A1 Collagen  alpha-1 (XXIII) Chain
COL29A1 Collagen  alpha-1 (XXIX) Chain
COL6A3
COL8A1 Collagen  alpha-1 (VIII) Chain
CORO1A Coronin-1A 
CUTA Acetylcholinesterase-Associated Protein 
CXCL12 stromal cell-derived factor 1
DAXX Death-associated protein 6
DR3 Death receptor 3. 
ERK Mitogen-activated protein kinase 
FADD Fas-associated protein with death domain, 
FAS TNF receptor superfamily 6
GAREM1 GRB2 associated regulator of MAPK1 subtype 1
GBR2 Growth factor receptor-bound protein 2 
GCSF Granulocyte-colony stimulating factor 
GM-CSF Granulocyte-macrophage colony-stimulating factor
GNGT2
GPSM3 G Protein Signaling Modulator 3 
HIC1 Hypermethylated in cancer 1
Beta-1,3-galactosyltransferase 4  
Brain-specific angiogenesis inhibitor 1-associated protein 2  
Brain-specific angiogenesis inhibitor 1-associated protein 
2 - Antisense 1 
BCL2-related protein A1  
Integrin, alpha L  
Collagen alpha-3(VI) chain  
guanine nucleotide-binding protein, gamma-transducing 










Gene Acronym Gene Name
RNF39 RING finger protein 39
RPS18 40S ribosomal protein S18 
RUNX1 Runt-related transcription factor 1
RUNX2 Runt-related transcription factor 2
RUNX3 Runt-related transcription factor 3
SFRP2 Secreted frizzled-related protein 2 
SHARPIN SHANK Associated RH Domain Interactor 
SNORD32A Small nucleolar RNA, C/D box 32A
STAT1 Signal transducer and activator of transcription 1 
TAB2 TGF-Beta Activated Kinase 1/MAP3K7 Binding Protein 2
TAB3 TGF-Beta Activated Kinase 1/MAP3K7 Binding Protein 3
TAK1 MAP3K7
TBID BH3 interacting-domain death agonist 
TCR T cell receptor
TGFβ Transforming Growth Factor Beta 1 
TLR9 Toll-like receptor 9
TMC6 Transmembrane Channel Like 6 
TNF Tumour Necrosis Factor
TNFR1 Tumour Necrosis Factor Receptor 1
TNFR2 Tumour Necrosis Factor Receptor 2
TRADD
TRAF1 TNF Receptor Associated Factor 1
TRAF2 TNF Receptor Associated Factor 2 
TRAF5 TNF Receptor Associated Factor 5 
TRAF6 TNF Receptor Associated Factor 6 
TRAIL TNF-related apoptosis-inducing ligand 
THBS1 Thrombospondin
UACA Uveal autoantigen with coiled-coil domains and ankyrin repeats 
USP18 Ubiquitin specific peptidase 18 
VEGF Vascular endothelial growth factor, 
ZAP70 Zeta Chain Of T Cell Receptor Associated Protein Kinase 70 
ZC3H12D zinc finger CCCH-type containing 12B 
ZNF217 Zinc finger protein 217 
cFOS FBJ murine osteosarcoma viral oncogene homolog 




             
Gene Acronym Gene Name
HOXB-AS3 HOXB Cluster Antisense RNA 1 
HPN Hepsin
HVEM Herpesvirus entry mediator 
IAPs inhibitor of apoptosis family of proteins 
IFI44L Interferon-induce protein 44-like
IFITM1








IRF1/2 Interferon regulatory factor 1/ 2
JNK c-Jun N-terminal kinases 
JUN-B JunB Proto-Oncogene, AP-1 Transcription Factor Subunit 
KSR1 Kinase suppressor of Ras 1 
LAT
LIGHT TNF superfamily member 14, 
LNPEP Leucyl/cystinyl aminopeptidase 
LTBR Lymphotoxin beta receptor 
MAP3K14-AS1 NF-kappa-B-inducing kinase – antisense 1
MAZ Myc-associated zinc finger protein 
MEKK Mitogen-activated protein kinase kinase kinase 
MEOX1 homeobox protein MOX-1 
MLH1 MutL homolog 1, colon cancer, nonpolyposis type 2 
MLL1 Histone-lysine N-methyltransferase 2A 
NEMO NF-kappa-B essential modulator 
NFkB nuclear factor-kappa-B 
NFkB1 Nuclear factor NF-kappa-B p105 subunit 
NFkB2 See NFkB definition 
NIK NF-kappa-B-inducing kinase 
NR4A2 nuclear receptor subfamily 4 group A
Nr13 Anti-apoptotic protein NR13 
OCSTAMP
P16 cyclin-dependent kinase inhibitor 2A 
P38 Mitogen-activated protein kinase 14 
P53 Tumor protein p53
PBX2
PDGF-bchain
PDGFRA platelet-derived growth factor receptor A 
PTPRCAP
Proenkephalin proenkephalin A 
RAF
RANK TNF ligand superfamily member 11
RAS Rat sarcoma viral oncogene homolog 
RELA P65
Interferon-induced transmembrane protein 1  
Insulin-like growth factor-binding protein 1/2  
 Inhibitor of nuclear factor kappa-B kinase subunit alpha 
 Inhibitor of nuclear factor kappa-B kinase subunit beta 
 Linker For Activation Of T Cells 
osteoclast stimulatory transmembrane protein 
Pre-B-cell leukemia transcription factor 2  
Platelet-derived growth factor subunit B  
Protein tyrosine phosphatase receptor type C-associated 
protein 
MAP kinase kinase kinase  
